Compounds > artesunic acid
Page last updated: 2024-09-24

artesunic acid

Cross-References

ID SourceID
PubMed CID105031
CHEMBL ID1967249
SCHEMBL ID12922911
MeSH IDM0289338

Synonyms (11)

Synonym
LS-14742
NCI60_039350
88495-63-0
artesunate ,
dihydroqinghaosusuccinate
nsc712571
182824-33-5
SCHEMBL12922911
CHEMBL1967249
4-oxo-4-[(1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl)oxy]butanoic acid
4-oxo-4-[[(1s,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid

Research

Studies (1,997)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (1.90)18.7374
1990's124 (6.21)18.2507
2000's562 (28.14)29.6817
2010's903 (45.22)24.3611
2020's370 (18.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials443 (21.21%)5.53%
Reviews130 (6.22%)6.00%
Case Studies144 (6.89%)4.05%
Observational15 (0.72%)0.25%
Other1,357 (64.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
irinotecan[no description available]medium20carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
phosphatidylcholines[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine
luminol[no description available]medium30
gold[no description available]medium20copper group element atom;
elemental gold
licochalcone b[no description available]medium10chalcones
artemether[no description available]medium17843artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
andrographolide[no description available]medium10carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
arteannuin b[no description available]medium10
ruthenium[no description available]medium10iron group element atom;
platinum group metal atom
artemisinin[no description available]medium18126organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
choline[no description available]medium10cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
mefloquine[no description available]medium286101
quinine[no description available]medium15436cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
niclosamide[no description available]medium10benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
hydroxychloroquine[no description available]medium20aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
chloroquine[no description available]medium16635aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
dextrothyroxine[no description available]medium30
imatinib mesylate[no description available]medium50methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
bafilomycin a[no description available]medium10
molnupiravir[no description available]medium10isopropyl ester;
ketoxime;
nucleoside analogue		anticoronaviral agent;
antiviral drug;
prodrug
atazanavir sulfate[no description available]medium20organic sulfate salt
ciclesonide[no description available]medium10organic molecular entity
favipiravir[no description available]medium10hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
cytidine[no description available]medium10cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
amodiaquine[no description available]medium18481aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
ritonavir[no description available]medium511,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
valine[no description available]medium20L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
nitazoxanide[no description available]medium20benzamides;
carboxylic ester
pyronaridine[no description available]medium4314aminoquinoline
thiazoles[no description available]medium201,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines[no description available]medium40diazine;
pyrazines		Daphnia magna metabolite
carbamates[no description available]medium20amino-acid anion
bms-790052[no description available]medium10biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor
cgp-56697[no description available]medium6326
amphotericin b[no description available]medium50antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
acetone[no description available]medium10ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
benzonidazole[no description available]medium10C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
praziquantel[no description available]medium3612isoquinolines
azomycin[no description available]medium10C-nitro compound;
imidazoles		antitubercular agent
remifentanil[no description available]medium10alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
valacyclovir[no description available]medium20L-valyl esterantiviral drug
valganciclovir[no description available]medium20L-valyl ester;
purines		antiviral drug;
prodrug
artenimol[no description available]medium19453
piperaquine[no description available]medium6024aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial
lgk974[no description available]medium10bipyridines;
pyrazines;
pyridines;
secondary carboxamide		Wnt signalling inhibitor
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
limestone[no description available]medium10calcium salt;
carbonate salt;
inorganic calcium salt;
one-carbon compound		antacid;
fertilizer;
food colouring;
food firming agent
cytarabine[no description available]medium50beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
abt-199[no description available]medium10aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
dinoprostone[no description available]medium60prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
ganciclovir[no description available]medium402-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
chalcone[no description available]medium10chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
temozolomide[no description available]medium80imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
bilirubin[no description available]medium21biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
verapamil[no description available]medium40aromatic ether;
nitrile;
polyether;
tertiary amino compound
lead[no description available]medium10carbon group element atom;
elemental lead;
metal atom		neurotoxin
sulfadoxine[no description available]medium16578pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
pyrimethamine[no description available]medium17886aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
lomustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
curcumin[no description available]medium20aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
artesunate[no description available]medium10artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
mannitol[no description available]medium10mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
gefitinib[no description available]medium10aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
adenosine diphosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
fluoxetine[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
fluorouracil[no description available]medium10nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
ribose[no description available]medium10D-ribose;
ribopyranose
fluphenazine[no description available]medium10N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
paclitaxel[no description available]medium30taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
benztropine[no description available]medium10diarylmethane
sertraline[no description available]medium20dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
thioridazine[no description available]medium10phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
procyanidin[no description available]medium10proanthocyanidin
oz 439[no description available]medium31
ferroquine[no description available]medium53
isosorbide dinitrate[no description available]medium10glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
isosorbide-5-mononitrate[no description available]medium10glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
lipoxin a4[no description available]medium10hydroxy polyunsaturated fatty acid;
lipoxin;
long-chain fatty acid		human metabolite;
metabolite
daunorubicin[no description available]medium30aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
artemotil[no description available]medium150artemisinin derivative
sesquiterpenes[no description available]medium627193
bisacodyl[no description available]medium10diarylmethane
camptothecin[no description available]medium20delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
peramivir[no description available]medium10
sorafenib[no description available]medium60(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
metformin[no description available]medium10guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
amoxicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
clarithromycin[no description available]medium10macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
glycerol[no description available]medium20alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
glutaral[no description available]medium10dialdehydecross-linking reagent;
disinfectant;
fixative
arsenic trioxide[no description available]medium30
rhein[no description available]medium10dihydroxyanthraquinone
aluminum[no description available]medium10boron group element atom;
elemental aluminium;
metal atom
primaquine[no description available]medium4821aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
quinidine gluconate[no description available]medium20D-gluconate adduct
quinidine[no description available]medium50cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
imiquimod[no description available]medium10imidazoquinolineantineoplastic agent;
interferon inducer
1,2-dimethylhydrazine[no description available]medium20hydrazinesalkylating agent;
carcinogenic agent
aspirin[no description available]medium30benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
clindamycin[no description available]medium111
lumefantrine[no description available]medium6728fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial
ticlopidine[no description available]medium10monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
clopidogrel carboxylic acid[no description available]medium10monocarboxylic acid;
monochlorobenzenes;
tertiary amino compound;
thienopyridine		drug metabolite;
marine xenobiotic metabolite
rifampin[no description available]medium20cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
methylene blue[no description available]medium84organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
mevalonic acid[no description available]medium103,5-dihydroxy-3-methylpentanoic acid
rutin[no description available]medium20disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
losartan potassium[no description available]medium40
atovaquone[no description available]medium238hydroxy-1,2-naphthoquinone
proguanil[no description available]medium4319biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
mefloquine carboxylic acid[no description available]medium10quinolines
desethylamodiaquine[no description available]medium95
carboplatin[no description available]medium30
deoxycytidine[no description available]medium20pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
gemcitabine[no description available]medium20organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
dinitrochlorobenzene[no description available]medium20C-nitro compound;
monochlorobenzenes		allergen;
epitope;
sensitiser
gadolinium[no description available]medium10f-block element atom;
lanthanoid atom
methotrexate[no description available]medium20dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
2-ethyl-2-oxazoline[no description available]medium10
oxazoles[no description available]medium101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
indomethacin[no description available]medium10aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
malondialdehyde[no description available]medium60dialdehydebiomarker
ovalbumin[no description available]medium40
epoxyazadiradione[no description available]medium10acetate ester;
cyclic terpene ketone;
epoxide;
furans;
limonoid;
pentacyclic triterpenoid		anti-inflammatory agent;
insecticide;
plant metabolite
iridium[no description available]medium10cobalt group element atom;
platinum group metal atom
tafenoquine[no description available]medium52(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid[no description available]medium20chromanol;
monocarboxylic acid;
phenols		antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor
methyl-thiohydantoin-tryptophan[no description available]medium20organonitrogen compound;
organooxygen compound
quinazolines[no description available]medium30azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
erastin[no description available]medium20aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide		antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor
spautin-1[no description available]medium10
fanasil, pyrimethamine drug combination[no description available]medium14171
tetramethylpyrazine[no description available]medium20alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
tilorone[no description available]medium10aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
quinacrine[no description available]medium10acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
withaferin a[no description available]medium1027-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide		antineoplastic agent;
apoptosis inducer
withanolides[no description available]medium10
calpain[no description available]medium20
niacinamide[no description available]medium30pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
meglumine antimoniate[no description available]medium11
allopurinol[no description available]medium11nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
dolutegravir[no description available]medium40difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
chloroquine diphosphate[no description available]medium10
piperidines[no description available]medium10
heme[no description available]medium80
cassine[no description available]medium10citraconoyl group
diminazene aceturate[no description available]medium10N-acetylglycinate saltantiparasitic agent;
trypanocidal drug
diminazene[no description available]medium20carboxamidine;
triazene derivative		antiparasitic agent;
trypanocidal drug
protectin d1[no description available]medium10dihydroxydocosahexaenoic acid;
protectin;
secondary allylic alcohol		anti-inflammatory agent;
apoptosis inhibitor;
hepatoprotective agent;
human xenobiotic metabolite;
neuroprotective agent;
PPARgamma agonist;
specialised pro-resolving mediator
palladium[no description available]medium10metal allergen;
nickel group element atom;
platinum group metal atom
thiophenes[no description available]medium10mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
benzothiophene[no description available]medium101-benzothiophenes;
benzothiophene
lactic acid[no description available]medium812-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
angiotensin ii[no description available]medium10amino acid zwitterion;
angiotensin II		human metabolite
histidine[no description available]medium10amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
rhenium[no description available]medium10manganese group element atom
dacarbazine[no description available]medium70dacarbazine
aminolevulinic acid[no description available]medium104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone[no description available]medium10
bromocriptine[no description available]medium10indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
4,7-dichloroquinoline[no description available]medium10
concanavalin a[no description available]medium40
pyrrolidine dithiocarbamate[no description available]medium10dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
phytochlorin[no description available]medium10
cyclin d1[no description available]medium50
luteolin[no description available]medium103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
quercetin[no description available]medium207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
erlotinib hydrochloride[no description available]medium20hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
adamantane[no description available]medium50adamantanes;
polycyclic alkane
s 53482[no description available]medium10benzoxazine;
dicarboximide;
organofluorine compound;
terminal acetylenic compound		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide;
teratogenic agent
glycerylphosphorylcholine[no description available]medium10glycerophosphocholine
adamantanine[no description available]medium10
folic acid[no description available]medium20folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
amantadine[no description available]medium10adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
betadex[no description available]medium20cyclodextrin
acetaminophen[no description available]medium21acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
d-alpha tocopherol[no description available]medium40alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
tocophersolan[no description available]medium20tocol
antipyrine[no description available]medium10pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
edaravone[no description available]medium10pyrazoloneantioxidant;
radical scavenger
ro13-9904[no description available]medium50
zithromax[no description available]medium158macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
trypan blue[no description available]medium10
neutral red[no description available]medium10hydrochlorideacid-base indicator;
dye;
two-colour indicator
cefotaxime[no description available]medium101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
beta-escin[no description available]medium10
lucanthone hydrochloride[no description available]medium195
beta-aminoarteether maleate[no description available]medium10maleate saltallergen
gamma-aminobutyric acid[no description available]medium20amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
scopoletin[no description available]medium10hydroxycoumarinplant growth regulator;
plant metabolite
arginine[no description available]medium10arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
natriuretic peptide, brain[no description available]medium11polypeptide
tacrolimus[no description available]medium10macrolide lactambacterial metabolite;
immunosuppressive agent
tyrphostin a9[no description available]medium10alkylbenzenegeroprotector
mocetinostat[no description available]medium10aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
acetylcysteine[no description available]medium62acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
resveratrol[no description available]medium10resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
sulfasalazine[no description available]medium10
calcium gluconate[no description available]medium10calcium saltnutraceutical
oxacillin[no description available]medium20penicillinantibacterial agent;
antibacterial drug
hydrogen sulfide[no description available]medium10gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent
sodium bisulfide[no description available]medium10
gyy 4137[no description available]medium10organic molecular entity
1,2,4-trioxane[no description available]medium10
dinitrofluorobenzene[no description available]medium10C-nitro compound;
organofluorine compound		agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
transforming growth factor beta[no description available]medium10
sodium hydroxide[no description available]medium10alkali metal hydroxide
nimodipine[no description available]medium102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
flavin-adenine dinucleotide[no description available]medium10flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group
arsenic[no description available]medium20metalloid atom;
pnictogen		micronutrient
artemisin[no description available]medium61
allicin[no description available]medium10botanical anti-fungal agent;
sulfoxide		antibacterial agent
cytidine diphosphate choline[no description available]medium10nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
selenium[no description available]medium10chalcogen;
nonmetal atom		micronutrient
retinol[no description available]medium10retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
triptolide[no description available]medium10diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
phenanthrenes[no description available]medium81
oxamniquine[no description available]medium20aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
zidovudine[no description available]medium10azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
nevirapine[no description available]medium10cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
lamivudine[no description available]medium30monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
epirubicin[no description available]medium10aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
transferrin[no description available]medium30
sincalide[no description available]medium10oligopeptide
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine[no description available]medium10cyanine dye;
indolium ion		fluorochrome
carbocyanines[no description available]medium20cyanine dye;
organic iodide salt		fluorochrome
phenytoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
arterolane[no description available]medium40
artemisone[no description available]medium40
metoprolol[no description available]medium11aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
trichlorfon[no description available]medium10organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
mangostin[no description available]medium10aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
chlorotonil a[no description available]medium10
aprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
itraconazole[no description available]medium10aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
disulfiram[no description available]medium10organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
celecoxib[no description available]medium10organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
captopril[no description available]medium10alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
rhodamine b[no description available]medium10organic chloride salt;
xanthene dye		fluorescent probe;
fluorochrome;
histological dye
3,3'-dihexyl-2,2'-oxacarbocyanine[no description available]medium10
miconazole[no description available]medium20dichlorobenzene;
ether;
imidazoles
pyrvinium[no description available]medium10quinolinium ionanthelminthic drug;
antineoplastic agent
hexachlorophene[no description available]medium10bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
fluconazole[no description available]medium10conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
l 743,872[no description available]medium10
8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline[no description available]medium11organonitrogen compound;
organooxygen compound
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
fullerene c60[no description available]medium10fullerenegeroprotector
baicalein[no description available]medium10trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
gw 257406x[no description available]medium20
metronidazole[no description available]medium10C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
vitamin k semiquinone radical[no description available]medium10
cannabidiol[no description available]medium10olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
chitosan[no description available]medium30
indole-3-carbinol[no description available]medium10indolyl alcoholantineoplastic agent;
plant metabolite
shikonin[no description available]medium10hydroxy-1,4-naphthoquinone
naphthoquinones[no description available]medium95
salicylates[no description available]medium10monohydroxybenzoateplant metabolite
stilbenes[no description available]medium10stilbene
3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid[no description available]medium10
pyrroles[no description available]medium30pyrrole;
secondary amine
atorvastatin[no description available]medium20aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
hydroxyproline[no description available]medium204-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
vancomycin[no description available]medium10glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
sb 203580[no description available]medium10imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
ha14-1[no description available]medium101-benzopyran
buthionine sulfoximine[no description available]medium20diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
triazoles[no description available]medium101,2,3-triazole
carbon tetrachloride[no description available]medium20chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
sirolimus[no description available]medium10antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
acyclovir[no description available]medium102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ferrostatin-1[no description available]medium20ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
artemisitene[no description available]medium10
deferoxamine[no description available]medium32acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
lopinavir[no description available]medium20amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
podophyllotoxin[no description available]medium10furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
sybr green i[no description available]medium10benzothiazolium ion;
cyanine dye;
quinolines;
tertiary amine		fluorescent dye
zinc protoporphyrin ix[no description available]medium10
paraquat[no description available]medium10organic cationgeroprotector;
herbicide
acetyl-aspartyl-glutamyl-valyl-aspartal[no description available]medium10tetrapeptideprotease inhibitor
3-nitrotyrosine[no description available]medium102-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid
tyrosine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
interleukin-8[no description available]medium40
isoprene[no description available]medium10alkadiene;
hemiterpene;
volatile organic compound		plant metabolite
brefeldin a[no description available]medium10macrolide antibioticPenicillium metabolite
sq-23377[no description available]medium10cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
phorbol-12-myristate[no description available]medium10
myelin oligodendrocyte glycoprotein (35-55)[no description available]medium10
desethylchloroquine[no description available]medium10aminoquinoline
decoquinate[no description available]medium10
emetine[no description available]medium10isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
carbostyril[no description available]medium10monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
simvastatin[no description available]medium20delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
taurocholic acid[no description available]medium10amino sulfonic acid;
bile acid taurine conjugate		human metabolite
artelinic acid[no description available]medium80
ammonium hydroxide[no description available]medium10azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
glutamic acid[no description available]medium10glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
pituitrin[no description available]medium10
trigonelline[no description available]medium10alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite
asparagine[no description available]medium10amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
prednisolone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
trimethoprim, sulfamethoxazole drug combination[no description available]medium33
chlorproguanil[no description available]medium146dichlorobenzene
dapsone[no description available]medium2411substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium10(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
pravastatin[no description available]medium103-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cephalosporin c[no description available]medium20cephalosporinfungal metabolite
ellagic acid[no description available]medium10catechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol		antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent
ng-nitroarginine methyl ester[no description available]medium20alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
pentoxifylline[no description available]medium32oxopurine
tribendimidine[no description available]medium81
5-fluoroorotic acid[no description available]medium10
orotic acid[no description available]medium10pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
sulfalene[no description available]medium119pyrazines;
sulfonamide antibiotic;
sulfonamide
4-hydroxypyridine[no description available]medium104-pyridones;
monohydroxypyridine
hypoxanthine[no description available]medium11nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
ursodeoxycholic acid[no description available]medium11bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
quassin[no description available]medium10triterpenoid
neoquassin[no description available]medium10triterpenoid
cantharidin[no description available]medium10cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
berberine[no description available]medium10alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
wogonin[no description available]medium10dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
oxymatrine[no description available]medium10
ibuprofen[no description available]medium11monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
warfarin[no description available]medium10benzenes;
hydroxycoumarin;
methyl ketone
triclabendazole[no description available]medium31aromatic ether
acid phosphatase[no description available]medium10
lenalidomide[no description available]medium10aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
thalidomide[no description available]medium10phthalimides;
piperidones
vitamin b 12[no description available]medium10
formaldehyde[no description available]medium10aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
bafilomycin a1[no description available]medium10cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
beta-lactams[no description available]medium20beta-lactam antibiotic allergen;
beta-lactam
5'-n-methylcarboxamideadenosine[no description available]medium10
ampicillin[no description available]medium10beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
fingolimod hydrochloride[no description available]medium10hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
sphingosine[no description available]medium10sphing-4-eninehuman metabolite;
mouse metabolite
sphingosine 1-phosphate[no description available]medium10sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
ferrous sulfate[no description available]medium10iron molecular entity;
metal sulfate		reducing agent
epidermal growth factor[no description available]medium10
ciprofloxacin[no description available]medium10aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
fumagillin[no description available]medium10antibiotic antifungal drug;
carboxylic ester;
dicarboxylic acid monoester;
meroterpenoid;
organooxygen heterocyclic antibiotic;
spiro-epoxide		angiogenesis inhibitor;
antibacterial drug;
antimicrobial agent;
antiprotozoal drug;
fungal metabolite;
methionine aminopeptidase 2 inhibitor
mebendazole[no description available]medium10aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
levamisole[no description available]medium106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
bisbenzimidazole[no description available]medium10bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
rka 182[no description available]medium10
leflunomide[no description available]medium10(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
isoxazoles[no description available]medium10isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
prizes[no description available]medium11carboxamidine;
monochloropyridine;
nitrile		environmental contaminant;
neonicotinoid insectide;
xenobiotic
nitrates[no description available]medium30monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
trichostatin a[no description available]medium10antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
tetracycline[no description available]medium86
pamaquine[no description available]medium10aminoquinoline
trimethoprim[no description available]medium11aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
2-propanol[no description available]medium10secondary alcohol;
secondary fatty alcohol		protic solvent
halofantrine[no description available]medium71phenanthrenes
fosfomycin[no description available]medium21epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
fosmidomycin[no description available]medium21hydroxamic acid;
phosphonic acids		antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor
methyl chloride[no description available]medium10chloromethanes;
methyl halides		marine metabolite;
mutagen;
refrigerant
bromine[no description available]medium10diatomic bromine
hexafluoroisopropanol[no description available]medium10organofluorine compound;
secondary alcohol		drug metabolite
fluoromethane[no description available]medium10fluorohydrocarbon;
fluoromethanes;
methyl halides		refrigerant
fluorine[no description available]medium10diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
cycloguanil[no description available]medium10triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
epiglucan[no description available]medium11
furamidine[no description available]medium10
chlorpheniramine[no description available]medium10monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
propylene glycol[no description available]medium10glycol;
propane-1,2-diols		allergen;
human xenobiotic metabolite;
mouse metabolite;
protic solvent
erythromycin[no description available]medium10cyclic ketone;
erythromycin
efavirenz[no description available]medium10acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
elafin[no description available]medium10
urea[no description available]medium10isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
diazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
dodecylamine[no description available]medium10primary aliphatic amine
foscarnet[no description available]medium10carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
isoliquiritigenin[no description available]medium10chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
thymidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine[no description available]medium20uridinesdrug metabolite;
fundamental metabolite;
human metabolite
croton oil[no description available]medium10N-acyl-hexosamine
endothelin-1[no description available]medium10
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid[no description available]medium10
thiobarbituric acid[no description available]medium10barbituratesallergen;
reagent
nitrites[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
acetonitrile[no description available]medium10aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
sodium dodecyl sulfate[no description available]medium10organic sodium saltdetergent;
protein denaturant
calca protein, human[no description available]medium10
dichloroacetic acid[no description available]medium11monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite
furosemide[no description available]medium10chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
chlorine[no description available]medium10halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
lissamine rhodamine b[no description available]medium10
fast red ta[no description available]medium10
laurocapram[no description available]medium10
ascorbic acid[no description available]medium10ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
hydroxypiperaquine[no description available]medium20
clove[no description available]medium43
ursolic acid[no description available]medium30hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
tridemorph[no description available]medium10morpholines;
tertiary amino compound		antifungal agrochemical
exudates[no description available]medium113
khellin[no description available]medium10furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
nsc-172755[no description available]medium43
loa[no description available]medium11
guaifenesin[no description available]medium10methoxybenzenes
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0medium92
2019 Novel Coronavirus Infection0medium92
2019-nCoV Disease0medium92
2019-nCoV Infection0medium92
A-Thalassemia0medium21
Abdominal Aortic Aneurysm0low10
Abdominal Pain0medium21
Aberrant Crypt Foci0low10
Abnormalities, Drug-Induced0low40
Abnormalities, Musculoskeletal0low10
Abscess, Amebic0low10
Absence Seizure0low10
Absence Seizures0low10
Acanthamebiasis0low10
Acanthamoeba Infection0low10
Acanthamoeba Meningoencephalitis0low10
Ache0low20
Acidosis0low10
Acidosis, Lactic0medium11
ACL Injuries0low10
ACL Tears0low10
Acne Rosacea0low10
Acquired Autoimmune Hemolytic Anemia0low30
Action Tremor0low10
Acute Brain Injuries0low10
Acute Confusional Senile Dementia0low30
Acute Coronary Syndrome0low10
Acute Disease0medium3117
Acute Edematous Pancreatitis0low30
Acute Encephalitis Syndrome0low10
Acute Febrile Encephalopathy0low10
Acute Hemolytic Transfusion Reaction0low30
Acute Kidney Failure0medium131
Acute Kidney Injury0medium131
Acute Kidney Insufficiency0medium131
Acute Liver Injury, Drug-Induced0medium91
Acute Lung Injury0low80
Acute Lymphoid Leukemia0low10
Acute Myelogenous Leukemia0low90
Acute Myeloid Leukemia0low90
Acute Myeloid Leukemia with Maturation0low90
Acute Myeloid Leukemia without Maturation0low90
Acute Necrotizing Encephalitis, Herpetic0low10
Acute Pancreatitis0low30
Acute Renal Failure0medium131
Acute Renal Injury0medium131
Acute Renal Insufficiency0medium131
Acute Respiratory Distress Syndrome0low60
Adenocarcinoma0low60
Adenocarcinoma Of Kidney0low10
Adenocarcinoma of Lung0low20
Adenocarcinoma, Basal Cell0low60
Adenocarcinoma, Granular Cell0low60
Adenocarcinoma, Oxyphilic0low60
Adenocarcinoma, Renal0low10
Adenocarcinoma, Renal Cell0low10
Adenocarcinoma, Tubular0low60
Adenoma, Malignant0low60
Adenomatous Polyposis Coli0low10
Adenomatous Polyposis Coli, Familial0low10
Adenomatous Polyposis of the Colon0low10
Adhesions, Tissue0low10
Adjuvant Arthritis0low80
Adult Respiratory Distress Syndrome0low60
Adverse Drug Event0medium136
Adverse Drug Reaction0medium136
African Lymphoma0low20
Age-Related Memory Disorders0low10
Age-Related Osteoporosis0low70
Aggression0low10
Aging0medium31
Agricultural Worker Disease0low10
Agricultural Worker's Disease0low10
Agricultural Workers' Diseases0low10
AIDS Seroconversion0low10
AIDS Seropositivity0low10
Airflow Obstruction, Chronic0low40
Airway Remodeling0low20
Airway Remodelling0low20
Airway Wall Remodelling0low20
ALL, Childhood0low10
Allergic Contact Dermatitis0low20
Allergic Encephalomyelitis0low10
Allergic Encephalomyelitis, Experimental0low10
Allergic Reaction0low20
Allergy0low20
Allergy, Drug0low10
Allodynia0low20
Allodynia, Mechanical0low20
Allodynia, Tactile0low20
Allodynia, Thermal0low20
Alloxan Diabetes0low60
Alpha Thalassemia0medium21
alpha-Thalassemia0medium21
Alveolar Bone Atrophy0low20
Alveolar Bone Loss0low20
Alveolar Echinococcosis, Hepatic0low10
Alveolar Process Atrophy0low20
Alveolar Resorption0low20
Alveolitis, Fibrosing0low30
Alzheimer Dementia0low30
Alzheimer Disease0low30
Alzheimer Disease, Early Onset0low30
Alzheimer Disease, Late Onset0low30
Alzheimer Sclerosis0low30
Alzheimer Syndrome0low30
Alzheimer Type Senile Dementia0low30
Alzheimer-Type Dementia (ATD)0low30
Alzheimer's Disease0low30
Alzheimer's Disease, Focal Onset0low30
Alzheimer's Diseases0low30
Amebiasis0low10
Amebic Meningoencephalitis0low10
Ameboma0low10
American Trypanosomiasis0low10
Amoebiasis0low10
Anaphylactic Reaction0low20
Anaphylactoid Reaction0low20
Anaphylactoid Shock0low20
Anaphylaxis0low20
Anasarca0low10
Androgen-Independent Prostatic Cancer0low10
Androgen-Independent Prostatic Neoplasms0low10
Androgen-Insensitive Prostatic Cancer0low10
Androgen-Insensitive Prostatic Neoplasms0low10
Androgen-Resistant Prostatic Cancer0low10
Androgen-Resistant Prostatic Neoplasms0low10
Anemia0medium3519
Anemia, Hemolytic0medium262
Anemia, Hemolytic, Acquired0medium262
Anemia, Hemolytic, Autoimmune0low30
Anemia, Hemolytic, Cold Antibody0low30
Anemia, Hemolytic, Idiopathic Acquired0low30
Anemia, Iron-Deficiency0low10
Anemia, Megaloblastic0low10
Anemia, Microangiopathic0medium262
Anemia, Sickle Cell0low10
Anemias, Iron-Deficiency0low10
Aneurysm, Abdominal Aortic0low10
Angiogenesis, Pathologic0low90
Angiogenesis, Pathological0low90
Animal Mammary Carcinoma0low10
ANLL0low90
Anorexia0medium21
Anoxemia0low10
Anoxia0low10
Anoxia-Ischemia, Brain0low10
Anoxia-Ischemia, Cerebral0low10
Anoxic-Ischemic Encephalopathy0low10
Anterior Cruciate Ligament Injuries0low10
Anterior Cruciate Ligament Injury0low10
Anterior Cruciate Ligament Tear0low10
Anterior Cruciate Ligament Tears0low10
Anterior Optic Neuritis0low10
Anti-HIV Positivity0low10
Anti-MuSK Myasthenia Gravis0low10
Anxiety0low20
Aortic Aneurysm, Abdominal0low10
Aortitis Syndrome0low10
Apoplexy0low20
Aprosodia0low10
Aprosodic Speech0low10
ARDS, Human0low60
Arrhythmia0low10
Arrhythmias, Cardiac0low10
Arrythmia0low10
Arteritis, Takayasu's0low10
Arthritis, Adjuvant0low80
Arthritis, Adjuvant-Induced0low80
Arthritis, Collagen-Induced0low80
Arthritis, Degenerative0low60
Arthritis, Experimental0low80
Arthritis, Rheumatoid0low100
Arthropathies0low10
Arthroses0low60
Arthrosis0low60
Asphyxia Neonatorum0low10
Asthma0low80
Asthma, Bronchial0low80
Asthmatic Airway Remodeling0low20
Asthmatic Airway Remodelling0low20
Asthmatic Airway Wall Remodeling0low20
Asthmatic Airway Wall Remodelling0low20
Astrocytoma, Grade IV0low120
Asymmetric Diabetic Proximal Motor Neuropathy0low10
Asymptomatic Colonization0low10
Asymptomatic Conditions0low10
Asymptomatic Diseases0low10
Asymptomatic Infections0low10
Asymptomatic States0low10
Ataxia0low20
Ataxia, Appendicular0low20
Ataxia, Limb0low20
Ataxia, Motor0low20
Ataxia, Sensory0low20
Ataxia, Truncal0low20
Ataxy0low20
Atherogenesis0low20
Atheroma0low20
Atheromatous Plaque0low20
Atheromatous Plaques0low20
Atherosclerosis0low20
Atherosclerotic Plaque0low20
Atherosclerotic Plaques0low20
Atonic Absence Seizure0low10
Atonic Absence Seizures0low10
Atonic Seizure0low10
Atonic Seizures0low10
Atrophy0low10
Aura0low10
Autoimmune Chronic Hepatitis0low10
Autoimmune Diabetes0low40
Autoimmune Disease0low10
Autoimmune Diseases0low10
Autoimmune Encephalomyelitis, Experimental0low10
Autoimmune Experimental Encephalomyelitis0low10
Autoimmune Experimental Myasthenia Gravis0low10
Autoimmune Haemolytic Anaemia0low30
Autoimmune Hemolytic Anemia0low30
Autoimmune Hepatitis0low10
Awakening Epilepsy0low10
B Virus Infection0low20
B-Cell Chronic Lymphocytic Leukemia0low10
B-Cell Leukemia, Chronic0low10
B-Cell Lymphoma0low20
B-Cell Malignancy, Low-Grade0low10
B-Lymphocytic Leukemia, Chronic0low10
B. burgdorferi Infection0low10
B16 Melanoma0low10
Babesia Infection0low40
Babesia Parasite Infection0low40
Babesiasis0low40
Babesiosis0low40
Bacteremia0low30
Bacterial Infections, Gram-Negative0low10
Balamuthia Infection0low10
Balamuthia mandrillaris CNS Infection0low10
Balamuthia mandrillaris Meningoencephalitis0low10
Basal Ganglia Diseases0low10
Basal Ganglia Disorders0low10
Behavior Disorders0medium11
Benign Neoplasms0medium311
Benign Neoplasms, Brain0low80
Berger Disease0medium21
Berger's Disease0medium21
Beriberi0medium11
Bewilderment0low10
Bilateral Headache0medium22
Bile Duct Cancer0low10
Bile Duct Neoplasms0low10
Bilharziasis0medium102
Birth Weight0medium11
Black Fever0medium51
Black Water Fever0low20
Blackwater Fever0low20
Bladder Cancer0low40
Bladder Neoplasms0low40
Bladder Tumors0low40
Blastocyst Disintegration0low50
Bleeding0medium21
Blood Clot0low10
Blood Poisoning0medium101
Blood Transfusion-Associated Adverse Reactions0low30
Bloodstream Infection0medium101
Body Weight0medium216
Bone Cancer0low20
Bone Diseases0low10
Bone Loss, Age-Related0low70
Bone Loss, Alveolar0low20
Bone Loss, Osteoclastic0low20
Bone Loss, Periodontal0low20
Bone Marrow Diseases0medium11
Bone Neoplasms0low20
Bone Resorption0low20
Borrelia burgdorferi Infection0low10
Brain Anoxia-Ischemia0low10
Brain Cancer0low80
Brain Diseases0low30
Brain Disorders0low30
Brain Edema0low10
Brain Hemorrhage, Cerebral0low10
Brain Hypoxia-Ischemia0low10
Brain Injuries0low10
Brain Injuries, Acute0low10
Brain Injuries, Focal0low10
Brain Ischemia0low20
Brain Ischemia-Anoxia0low10
Brain Ischemia-Hypoxia0low10
Brain Lacerations0low10
Brain Metastases0low80
Brain Neoplasm, Primary0low80
Brain Neoplasms0low80
Brain Neoplasms, Benign0low80
Brain Neoplasms, Malignant0low80
Brain Neoplasms, Malignant, Primary0low80
Brain Neoplasms, Primary Malignant0low80
Brain Swelling0low10
Brain Tumor, Primary0low80
Brain Tumor, Recurrent0low80
Brain Tumors0low80
Brain Vascular Disorders0low10
Break-Bone Fever0low40
Breakbone Fever0low40
Breast Cancer0medium204
Breast Carcinoma0medium204
Breast Neoplasms0medium204
Breast Tumors0medium204
Bright Disease0low10
Bronchial Asthma0low80
Bronchial Hyperreactivity0low20
Burkitt Cell Leukemia0low20
Burkitt Leukemia0low20
Burkitt Lymphoma0low20
Burkitt Tumor0low20
Burkitt's Leukemia0low20
Burkitt's Lymphoma0low20
Burkitt's Tumor0low20
Burns0low10
Burns, Chemical0low10
Cafe-au-Lait Spots with Pulmonic Stenosis0low10
Cancer0medium311
Cancer of Bile Duct0low10
Cancer of Bladder0low40
Cancer of Bone0low20
Cancer of Brain0low80
Cancer of Breast0medium204
Cancer of Cervix0medium51
Cancer of Colon0low70
Cancer of Endometrium0low20
Cancer of Esophagus0low30
Cancer of Head0low20
Cancer of Head and Neck0low20
Cancer of Kidney0low20
Cancer of Liver0low160
Cancer of Lung0medium221
Cancer of Mouth0low10
Cancer of Nasopharynx0low10
Cancer of Neck0low20
Cancer of Ovary0low90
Cancer of Pancreas0low40
Cancer of Pituitary0low10
Cancer of Prostate0low50
Cancer of Skin0low30
Cancer of Stomach0low30
Cancer of the Bile Duct0low10
Cancer of the Bladder0low40
Cancer of the Bone0low20
Cancer of the Brain0low80
Cancer of the Breast0medium204
Cancer of the Cervix0medium51
Cancer of the Colon0low70
Cancer of the Endometrium0low20
Cancer of the Esophagus0low30
Cancer of the Head0low20
Cancer of the Head and Neck0low20
Cancer of the Kidney0low20
Cancer of the Liver0low160
Cancer of the Lung0medium221
Cancer of the Mouth0low10
Cancer of the Nasopharynx0low10
Cancer of the Neck0low20
Cancer of the Ovary0low90
Cancer of the Pancreas0low40
Cancer of the Pituitary0low10
Cancer of the Prostate0low50
Cancer of the Retina0low10
Cancer of the Skin0low30
Cancer of the Stomach0low30
Cancer of the Thyroid0low10
Cancer of the Tongue0low20
Cancer of the Uterine Cervix0medium51
Cancer of the Vulva0low10
Cancer of Thyroid0low10
Cancer of Tongue0low20
Cancer of Vulva0low10
Cancer, Hepatocellular0low160
Cancer, Retinal0low10
Candida Infection0low10
Candidiasis0low10
Cane-Cutter Fever0low10
Canicola Fever0low10
Canine Diseases0medium21
Carcinogenesis0low30
Carcinoma0low40
Carcinoma in Situ0low10
Carcinoma of Endometrium0low20
Carcinoma, Anaplastic0low40
Carcinoma, Cribriform0low60
Carcinoma, Ductal, Breast0low10
Carcinoma, Epidermoid0low60
Carcinoma, Granular Cell0low60
Carcinoma, Hepatocellular0low150
Carcinoma, Hypernephroid0low10
Carcinoma, Infiltrating Duct0low10
Carcinoma, Intraepithelial0low10
Carcinoma, Invasive Ductal, Breast0low10
Carcinoma, Mammary Ductal0low10
Carcinoma, Non-Small Cell Lung0medium131
Carcinoma, Non-Small-Cell Lung0medium131
Carcinoma, Ovarian Epithelial0low10
Carcinoma, Planocellular0low60
Carcinoma, Preinvasive0low10
Carcinoma, Renal Cell0low10
Carcinoma, Spindle-Cell0low40
Carcinoma, Squamous0low60
Carcinoma, Squamous Cell0low60
Carcinoma, Squamous Cell of Head and Neck0low10
Carcinoma, Thymic0low10
Carcinoma, Transitional Cell0low10
Carcinoma, Tubular0low60
Carcinoma, Undifferentiated0low40
Carcinomatosis0low40
Cardiac Arrhythmia0low10
Cardiac Arrhythmias0low10
Cardiac Diseases0medium11
Cardiac Disorders0medium11
Cardiac Dysrhythmia0low10
Cardiac Failure0low10
Cardiovascular Diseases0low30
Cardiovascular Stroke0low10
Carditis0low20
Castration-Resistant Prostatic Cancer0low10
Castration-Resistant Prostatic Neoplasms0low10
Cell Transformation, Neoplastic0low20
Cell Transformation, Viral0low10
Central Nervous System Cysticercosis0low10
Central Nervous System Disease0medium21
Central Nervous System Diseases0medium21
Central Nervous System Disorder0medium21
Central Nervous System Disorders0medium21
Central Nervous System Disorders, Intracranial0low30
Central Nervous System Intracranial Disorders0low30
Central Nervous System Neoplasm0low10
Central Nervous System Neoplasms0low10
Central Nervous System Neoplasms, Primary0low10
Central Nervous System Origin Vertigo0medium22
Central Nervous System Protozoal Infections0low10
Central Nervous System Tumor0low10
Central Nervous System Tumors0low10
Central Retinal Edema, Cystoid0low10
Centrala nervsystemets sjukdomar@sv0medium21
Cephalalgia0medium22
Cephalgia0medium22
Cephalodynia0medium22
Cerebellar Diseases0low10
Cerebellar Disorders0low10
Cerebellar Dysfunction0low10
Cerebellar Syndromes0low10
Cerebellum Diseases0low10
Cerebral Anoxia-Ischemia0low10
Cerebral Coenurosis0low10
Cerebral Cysticercosis0low10
Cerebral Edema0low10
Cerebral Edema, Cytotoxic0low10
Cerebral Edema, Vasogenic0low10
Cerebral Hemorrhage0low10
Cerebral Hypoxia-Ischemia0low10
Cerebral Infarction, Middle Cerebral Artery0low30
Cerebral Ischemia0low20
Cerebral Ischemia-Anoxia0low10
Cerebral Ischemia-Hypoxia0low10
Cerebral Malaria0medium6512
Cerebral Parenchymal Hemorrhage0low10
Cerebral Protozoal Infections0low10
Cerebral Stroke0low20
Cerebromeningitis0low10
Cerebrovascular Accident0low20
Cerebrovascular Accident, Acute0low20
Cerebrovascular Apoplexy0low20
Cerebrovascular Diseases0low10
Cerebrovascular Disorders0low10
Cerebrovascular Insufficiency0low10
Cerebrovascular Occlusion0low10
Cerebrovascular Stroke0low20
Cervical Cancer0medium51
Cervical Neoplasms0medium51
Cervix Cancer0medium51
Cervix Dysplasia0medium11
Cervix Neoplasms0medium51
Chagas Disease0low10
Chagas' Disease0low10
Chemical and Drug Induced Liver Injury0medium91
Chemical and Drug Induced Liver Injury, Chronic0low10
Chemical Burns0low10
Chemical-Induced Liver Injury, Chronic0low10
Chemically-Induced Liver Injury, Chronic0low10
Chemically-Induced Liver Toxicity0medium91
Cholangiocarcinoma0low10
Cholangiocellular Carcinoma0low10
Cholera Infantum0medium22
Chorea0low10
Chorea Disorders0low10
Chorea Syndromes0low10
Chorea, Benign Hereditary0low10
Chorea, Chronic Progressive0low10
Chorea, Rheumatic0low10
Chorea, Senile0low10
Chorea, Sydenham0low10
Choreatic Disorders0low10
Choreatic Syndromes0low10
Choreic Movement0low10
Choreiform Movement0low10
Choroby OUN@pl0medium21
Choroid Neovascularization0low10
Choroidal Neovascularization0low10
Chromophil Renal Cell Carcinoma0low10
Chromophobe Renal Cell Carcinoma0low10
Chromosome-Defective Micronuclei0low10
Chronic Airflow Obstruction0low40
Chronic Drug-Induced Liver Injury0low10
Chronic Fatigue and Immune Dysfunction Syndrome0low10
Chronic Fatigue Disorder0low10
Chronic Fatigue Syndrome0low10
Chronic Fatigue-Fibromyalgia Syndrome0low10
Chronic Lung Injury0low30
Chronic Lymphocytic Leukemia0low10
Chronic Obstructive Airway Disease0low40
Chronic Obstructive Lung Disease0low40
Chronic Obstructive Pulmonary Disease0low40
Chronic Obstructive Pulmonary Diseases0low40
Cicatrix0low20
Cicatrix, Hypertrophic0low40
Cicatrization0low20
Circulatory Collapse0low30
Circulatory Failure0low30
Cirrhoses, Experimental Liver0low20
Cirrhosis0low40
Cirrhosis, Experimental Liver0low20
Cirrhosis, Liver0low60
Classical Dengue0low40
Classical Dengue Fever0low40
Clear Cell Renal Carcinoma0low10
Clear Cell Renal Cell Carcinoma0low10
Clonic Seizure0low10
Clonic Seizures0low10
Clonorchiasis0low70
Clonorchis Infection0low70
Clonorchis sinensis Infection0low70
Cluttering0low10
CNS Cysticercosis0low10
CNS Disease0medium21
CNS Diseases0medium21
CNS Disorders, Intracranial0low30
CNS Neoplasm0low10
CNS Neoplasms0low10
CNS Origin Vertigo0medium22
CNS Protozoal Infections0low10
Co-infection0low70
COAD0low40
Coagulation, Disseminated Intravascular0low30
Coarse Tremor0low10
Coinfection0low70
Cold Agglutinin Disease0low30
Cold Antibody Disease0low30
Cold Antibody Hemolytic Anemia0low30
Colicky Pain0medium21
Colitis0low10
Colitis Gravis0low30
Colitis, Ulcerative0low30
Collagen Arthritis0low80
Collecting Duct Carcinoma0low10
Collecting Duct Carcinoma (Kidney)0low10
Collecting Duct Carcinoma of the Kidney0low10
Colon Cancer0low70
Colon Neoplasms0low70
Colonic Cancer0low70
Colonic Neoplasms0low70
Colorectal Cancer0medium91
Colorectal Carcinoma0medium91
Colorectal Neoplasms0medium91
Colorectal Tumors0medium91
Coma0medium32
Comatose0medium32
Communicable Diseases0low10
Communicable Diseases, Emerging0low10
Communicable Diseases, Imported0low10
Communicable Diseases, Re-Emerging0low10
Communicable Diseases, Reemerging0low10
Complex Partial Seizure0low10
Complex Partial Seizures0low10
Complication, Postoperative0low10
Complications, Infectious Pregnancy0medium102
Complications, Parasitic Pregnancy0medium2211
Confusion0low10
Confusion, Post-Ictal0low10
Confusion, Reactive0low10
Confusional State0low10
Congestive Heart Failure0low10
Consumption Coagulopathy0low30
Continuous Tremor0low10
Convulsion0low10
Convulsion, Non-Epileptic0low10
Convulsions0low10
Convulsive Seizure0low10
Convulsive Seizures0low10
Coordination Impairment0low20
COPD0low40
Corneal Angiogenesis0low10
Corneal Neovascularization0low10
Coronavirus Disease 20190medium92
Coronavirus Disease-190medium92
Coronavirus Infections0low20
COVID-190medium92
COVID-19 Pandemic0medium92
COVID-19 Pandemics0medium92
COVID-19 Virus Disease0medium92
COVID-19 Virus Infection0medium92
COVID190medium92
Cranial Pain0medium22
Critical Illness0low30
Critically Ill0low30
Cryptogenic Fibrosing Alveolitis0low10
CVA (Cerebrovascular Accident)0low20
Cysticercosis, Brain0low10
Cysticercosis, Central Nervous System0low10
Cystoid Macular Dystrophy0low10
Cystoid Macular Edema0low10
Cystoid Macular Edema, Postoperative0low10
Cytokine Release Syndrome0low10
Cytokine Storm0low10
Cytokine Storm Syndrome0low10
Cytomegalic Inclusion Disease0medium141
Cytomegalovirus0medium211
Cytomegalovirus Infections0medium141
Cytotoxic Brain Edema0low10
Cytotoxic Cerebral Edema0low10
Darkness Tremor0low10
Deafness, Transitory0low10
Deficiency of Glucose-6-Phosphate Dehydrogenase0medium84
Deficiency, Glucosephosphatase0medium11
Deficiency, Glucosephosphate Dehydrogenase0medium84
Deficiency, GPD0medium84
Deficiency, Oxygen0low10
Deficiency, Thiamine0medium11
Degenerative Diseases, Central Nervous System0low10
Degenerative Diseases, Nervous System0low10
Degenerative Diseases, Neurologic0low10
Degenerative Diseases, Spinal Cord0low10
Degenerative Neurologic Diseases0low10
Degenerative Neurologic Disorders0low10
Delayed Effects, Prenatal Exposure0medium51
Delayed Hemolytic Transfusion Reaction0low30
Delayed Hypersensitivity0low40
Delayed Serologic Transfusion Reaction0low30
Dementia, Alzheimer Type0low30
Dementia, Presenile0low30
Dementia, Primary Senile Degenerative0low30
Dementia, Senile0low30
Dengue0low40
Dengue Fever0low40
Depression0low10
Dermatitis0low10
Dermatitis, Allergic Contact0low20
Dermatitis, Allergic Eczematous0low20
Dermatitis, Atopic0low10
Dermatitis, Contact, Allergic0low20
Diabetes Mellitus0low10
Diabetes Mellitus, Brittle0low40
Diabetes Mellitus, Experimental0low60
Diabetes Mellitus, Gestational0low10
Diabetes Mellitus, Insulin-Dependent0low40
Diabetes Mellitus, Insulin-Dependent, 10low40
Diabetes Mellitus, Juvenile-Onset0low40
Diabetes Mellitus, Ketosis-Prone0low40
Diabetes Mellitus, Sudden-Onset0low40
Diabetes Mellitus, Type 10low40
Diabetes Mellitus, Type I0low40
Diabetes, Autoimmune0low40
Diabetes, Gestational0low10
Diabetes, Pregnancy-Induced0low10
Diabetic Amyotrophy0low10
Diabetic Asymmetric Polyneuropathy0low10
Diabetic Autonomic Neuropathy0low10
Diabetic Cardiomyopathies0low10
Diabetic Mononeuropathy0low10
Diabetic Mononeuropathy Simplex0low10
Diabetic Neuralgia0low10
Diabetic Neuropathies0low10
Diabetic Neuropathy, Painful0low10
Diabetic Polyneuropathy0low10
Diabetic Retinopathy0low10
Diagnosis, Psychiatric0medium11
Diarrhea0medium21
Diathesis0medium21
Diffuse Large B-Cell Lymphoma0low20
Diffuse Large-Cell Lymphoma0low20
Diffuse Mixed Small and Large Cell Lymphoma0low10
Diffuse Mixed-Cell Lymphoma0low10
Diffuse Small Cleaved-Cell Lymphoma0low10
Diffuse Undifferentiated Lymphoma0low10
Diffuse Well-Differentiated Lymphocytic Lymphoma0low10
Diffuse, Large B-Cell, Lymphoma0low20
Disbacteriosis0low20
Disbiosis0low20
Disease Exacerbation0low40
Disease Models, Animal0medium832
Disease Progression0low40
Disease Resistance0low10
Disease Susceptibility0medium21
Diseases of Immune System0low10
Disintegration of Blastocyst0low50
Disintegration of Embryo0low50
Disorientation0low10
Disrupted In B-Cell Malignancy0low10
Disseminated Coagulation, Intravascular0low30
Disseminated Intravascular Coagulation0low30
Dizziness0low10
Dizzyness0low10
Doenu00E7as do Sistema Nervoso Central@pt0medium21
Dog Diseases0medium21
Dropsy0low10
Drug Allergy0low10
Drug Hypersensitivity0low10
Drug Side Effects0medium136
Drug Toxicity0medium136
Drug-Induced Abnormalities0low40
Drug-Induced Acute Liver Injury0medium91
Drug-Induced Liver Disease0medium91
Drug-Induced Liver Injury0medium91
Drug-Induced Liver Injury, Chronic0low10
Drug-Related Side Effects and Adverse Reactions0medium136
Dys-symbiosis0low20
Dysbacteriosis0low20
Dysbiosis0low20
Dyscoordination0low20
Dysglossia0low10
Dyskinesias, Paroxysmal0low10
Dyslalia0low10
Dysmyelopoietic Syndromes0low10
Dyssynergia0low20
Dysuria0medium11
E coli Infections0low20
E. coli Infection0low20
Early Onset Alzheimer Disease0low30
Ebola Hemorrhagic Fever0low20
Ebola Infection0low20
Ebola Virus Disease0low20
Ebola Virus Infection0low20
Ebolavirus Infection0low20
EBV Infections0low10
Echinococcosis, Hepatic0low10
Echinococcosis, Hepatic Alveolar0low10
Ectoparasitic Infestations0low10
Eczema, Atopic0low10
Eczema, Infantile0low10
Edema0low10
Edema, Pulmonary0low10
Edemas, Pulmonary0low10
Electrocardiogram QT Prolonged0medium21
Electrolytes0low10
Elevated Cholesterol0low10
Embolic Infarction, Middle Cerebral Artery0low30
Embolus, Middle Cerebral Artery0low30
Embryo Death0low50
Embryo Disintegration0low50
Embryo Loss0low50
Embryo Resorption0low50
Embryopathies0low10
Emergencies0low10
Emesis0medium95
Encephalitis, Herpes Simplex0low10
Encephalitis, JC Polyomavirus0low10
Encephalomeningitis0low10
Encephalomyelitis, Allergic0low10
Encephalomyelitis, Autoimmune, Experimental0low10
Encephalomyelitis, Experimental Autoimmune0low10
Encephalomyelitis, Myalgic0low10
Encephalon Diseases0low30
Encephalopathy0low30
Encephalopathy, Anoxic-Ischemic0low10
Encephalopathy, Febrile0low10
Encephalopathy, Hepatic0low10
Encephalopathy, Hepatocerebral0low10
Encephalopathy, Hypoxic-Ischemic0low10
Encephalopathy, Ischemic0low20
Encephalopathy, Portal-Systemic0low10
Encephalopathy, Portosystemic0low10
Endometrial Cancer0low20
Endometrial Carcinoma0low20
Endometrial Neoplasms0low20
Endometrium Cancer0low20
Endotoxemia0low10
Endotoxin Shock0low10
Enfermedades del Sistema Nervioso Central@es0medium21
Enlarged Liver0low20
Enlarged Spleen0low10
Enteric Fever0low10
Enterically-Transmitted Non-A, Non-B Hepatitis0low10
Epidemic Non-A, Non-B Hepatitis0low10
Epidermolysis Bullosa Junctionalis, Disentis Type0low10
Epidermolysis Bullosa Junctionalis, Herlitz Type0low10
Epidermolysis Bullosa Junctionalis, Progressive0low10
Epidermolysis Bullosa Junctionalis, Severe Nonlethal0low10
Epidermolysis Bullosa Letalis0low10
Epidermolysis Bullosa Progressiva0low10
Epidermolysis Bullosa, Generalized Atrophic Benign0low10
Epidermolysis Bullosa, Junctional0low10
Epidermolysis Bullosa, Junctional, Herlitz Type0low10
Epidermolysis Bullosa, Junctional, Herlitz-Pearson Type0low10
Epilepsy0low10
Epilepsy, Cryptogenic0low10
Epileptic Seizure0low10
Epileptic Seizures0low10
Epithelial Neoplasms, Malignant0low40
Epithelial Ovarian Cancer0low10
Epithelial Ovarian Carcinoma0low10
Epithelial Tumors, Malignant0low40
Epithelioma0low40
Epstein-Barr Virus Infection0low10
Epstein-Barr Virus Infections0low10
ER-Negative PR-Negative HER2-Negative Breast Cancer0low10
ER-Negative PR-Negative HER2-Negative Breast Neoplasms0low10
Erythematotelangiectatic Rosacea0low10
Erythrophagocytic Lymphohistiocytosis, Familial0low30
Escherichia coli Infections0low20
Esophageal Cancer0low30
Esophageal Neoplasms0low30
Esophageal Squamous Cell Carcinoma0low10
Esophagus Cancer0low30
Esophagus Neoplasm0low30
ET-NANBH0low10
Exanthem0low10
Exanthema0low10
Experimental Allergic Encephalomyelitis0low10
Experimental Autoimmune Encephalomyelitis0low10
Experimental Autoimmune Myasthenia Gravis, Passive Transfer0low10
Experimental Diabetes Mellitus0low60
Experimental Hepatoma0low40
Experimental Hepatomas0low40
Experimental Liver Cirrhoses0low20
Experimental Liver Cirrhosis0low20
Experimental Liver Neoplasms0low40
Experimental Lung Inflammation0low10
Experimental Mammary Neoplasms0low10
Experimental Melanoma0low10
Experimental Melanomas0low10
Experimental Myasthenia0low10
Experimental Myasthenia Gravis0low10
Experimental Neoplasms0low30
Extrahepatic Cholangiocarcinoma0low10
Extrapyramidal Disorders0low10
Extravascular Hemolysis0medium384
Eye Burns0low10
Eye Cancer, Retinoblastoma0low20
Eye Hemorrhage0low10
Familial Adenomatous Polyposis0low10
Familial Adenomatous Polyposis Coli0low10
Familial Adenomatous Polyposis of the Colon0low10
Familial Alzheimer Disease (FAD)0low30
Familial Erythrophagocytic Lymphohistiocytosis0low30
Familial Hemophagocytic Histiocytosis0low30
Familial Hemophagocytic Lymphocytosis0low30
Familial Hemophagocytic Lymphohistiocytosis0low30
Familial Hemophagocytic Reticulosis0low30
Familial Histiocytic Reticulosis0low30
Familial Idiopathic Pulmonary Fibrosis0low10
Familial Intestinal Polyposis0low10
Familial Multiple Polyposi0low10
Familial Multiple Polyposis0low10
Familial Multiple Polyposis Syndrome0low10
Familial Polyposis Coli0low10
Familial Polyposis of the Colon0low10
Familial Polyposis Syndrome0low10
Familial Retinoblastoma0low20
Fasciola Infection0medium81
Fascioliasis0medium81
Fasciolopsiasis0medium21
Fasting Hypoglycemia0low20
Fatigue Syndrome, Chronic0low10
Fatigue Syndrome, Postviral0low10
Fatty Liver0low10
Fatty Liver, Nonalcoholic0low10
Fatty Streak, Arterial0low20
Febrile Non-Hemolytic Transfusion Reaction0low30
Fetal Death0low20
Fetal Demise0low20
Fetal Diseases0low10
Fetal Mummification0low20
Fetal Resorption0low20
Fever0medium3118
Fever of Unknown Origin0medium21
Fibroatheroma0low20
Fibroatheromatous Plaques0low20
Fibrocystic Pulmonary Dysplasia0low10
Fibroses, Pulmonary0low30
Fibrosing Alveolitis, Cryptogenic0low10
Fibrosis0low40
Fibrosis, Liver0low60
Fibrosis, Pulmonary0low30
Fine Tremor0low10
Fish Diseases0low10
Focal Brain Injuries0low10
Focal Onset Alzheimer's Disease0low30
Foot Injuries0low10
Fowl Paralysis0low10
Fulminant Hepatic Failure with Cerebral Edema0low10
Functional Gastrointestinal Disorders0medium22
G6PD Deficiency0medium84
Gangrene0low10
Gastric Cancer0low30
Gastric Cancer, Familial Diffuse0low30
Gastric Neoplasms0low30
Gastric Ulcer0low30
Gastrointestinal Diseases0medium22
Gastrointestinal Disorders0medium22
Gastrointestinal Disorders, Functional0medium22
Generalized Absence Seizure0low10
Generalized Absence Seizures0low10
Generalized Headache0medium22
Generalized Tonic-Clonic Seizures0low10
Genotoxicant-Induced Micronuclei0low10
Germinoblastoma0low20
Gestational Diabetes0low10
Giant Cell Glioblastoma0low120
Gierke Disease0medium11
Gierke's Disease0medium11
Glial Cell Tumors0low30
Glioblastoma0low120
Glioblastoma Multiforme0low120
Glioblastoma, Retinal0low20
Glioma0low30
Glioma, Retinal0low20
Glomerulonephritis0low10
Glomerulonephritis, IGA0medium21
Glomerulonephritis, Lupus0low10
Glucose 6 Phosphate Dehydrogenase Deficiency0medium84
Glucose-6-Phosphatase Deficiency0medium11
Glucose-6-Phosphate Dehydrogenase Deficiency0medium84
Glucosephosphatase Deficiency0medium11
Glucosephosphate Dehydrogenase Deficiencies0medium84
Glucosephosphate Dehydrogenase Deficiency0medium84
Glycogen Storage Disease 1 (GSD I)0medium11
Glycogen Storage Disease Type I0medium11
Glycogenosis 10medium11
GPD Deficiency0medium84
Gram-Negative Bacterial Infections0low10
Granulocytic Leukemia, Chronic0low10
Granulomatous Rosacea0low10
Grawitz Tumor0low10
Grippe0low30
Haemolysis0medium384
Haemolytic Anaemia0medium262
Harding Passey Melanoma0low10
HbS Disease0low10
Head and Neck Cancer0low20
Head and Neck Neoplasm0low20
Head and Neck Neoplasms0low20
Head and Neck Squamous Cell Carcinoma0low10
Head And Neck Squamous Cell Carcinomas0low10
Head Cancer0low20
Head Neoplasm0low20
Head Neoplasms0low20
Head Pain0medium22
Head, Neck Neoplasms0low20
Headache0medium22
Hearing Impairment0low10
Hearing Loss0low10
Hearing Loss, Transitory0low10
Heart Attack0low10
Heart Decompensation0low10
Heart Diseases0medium11
Heart Disorders0medium11
Heart Failure0low10
Heart Failure, Congestive0low10
Heart Failure, Left-Sided0low10
Heart Failure, Right-Sided0low10
Heat Stroke0low10
Heatstroke0low10
Helicobacter Infections0low20
Hematoma0low10
Hematoma, Subdural0low30
Hematoma, Subdural, Acute0low10
Hematopoetic Myelodysplasia0low10
Hemicrania0medium22
Hemoglobin H Disease0medium21
Hemoglobin S Disease0low10
Hemoglobinuria0low10
Hemolysis0medium384
Hemolytic Anemia0medium262
Hemolytic Anemia Due to G6PD Deficiency0medium84
Hemolytic Anemia, Acquired0medium262
Hemolytic Anemia, Autoimmune0low30
Hemolytic Transfusion Reaction0low30
Hemophagocytic Lymphohistiocytosis Familial -10low30
Hemophagocytic Lymphohistiocytosis, Familial0low30
Hemophagocytic Lymphohistiocytosis, Familial, 10low30
Hemophagocytic Reticulosis, Familial0low30
Hemophagocytic Syndrome0low30
Hemophagocytic Syndrome, Infection-Associated0low30
Hemophagocytic Syndrome, Reactive0low30
Hemophagocytic Syndromes0low30
Hemophthalmos0low10
Hemorrhage0medium21
Hemorrhage, Cerebral0low10
Hemorrhage, Cerebrum0low10
Hemorrhage, Eye0low10
Hemorrhage, Subarachnoid0low10
Hemorrhage, Subdural0low30
Hemorrhage, Subdural, Acute0low10
Hemorrhagic Fever, Ebola0low20
Hemorrhagic Shock0low20
Hepatic Cancer0low160
Hepatic Cirrhosis0low60
Hepatic Cirrhosis, Experimental0low20
Hepatic Coma0low10
Hepatic Encephalopathy0low10
Hepatic Neoplasms0low160
Hepatic Stupor0low10
Hepatitis B0low10
Hepatitis B Virus Infection0low10
Hepatitis E0low10
Hepatitis, Autoimmune0low10
Hepatitis, Chronic, Drug-Induced0low10
Hepatitis, Chronic, Drug-Related0low10
Hepatitis, Drug-Induced0medium91
Hepatitis, Toxic0medium91
Hepatitis, Viral, Non-A, Non-B, Enterically-Transmitted0low10
Hepatitis, Water-Borne0low10
Hepatocellular Cancer0low160
Hepatocellular Carcinoma0low150
Hepatocerebral Encephalopathy0low10
Hepatoma0low150
Hepatoma, Experimental0low40
Hepatoma, Morris0low40
Hepatoma, Novikoff0low40
Hepatomas, Experimental0low40
Hepatomegaly0low20
Hepatorenal Glycogen Storage Disease0medium11
Hereditary Chorea0low10
Hereditary Polyposis Coli0low10
Hereditary Progressive Chorea Without Dementia0low10
Hereditary Retinoblastoma0low20
Herlitz Disease0low10
Herlitz-Pearson Type Epidermolysis Bullosa0low10
Herlitz-Pearson-Type Epidermolysis Bullosa0low10
Herlitz's Disease0low10
Herpes Encephalitis0low10
Herpes Simplex0low10
Herpes Simplex Encephalitis0low10
Herpes Simplex Meningoencephalitis0low10
Herpes Simplex Virus Infection0low10
Herpesviridae Infections0low20
Herpesvirus 4 Infections, Human0low10
Herpesvirus Infections0low20
Herpetic Acute Necrotizing Encephalitis0low10
Herpetic Encephalitis0low10
Herpetic Meningoencephalitis0low10
High Cholesterol Levels0low10
Histiocytic Lymphoma0low20
Histiocytic Lymphoma, Diffuse0low20
Histiocytic Sarcoma0low10
Histiocytosis, Malignant0low10
HIV Antibody Positivity0low10
HIV Coinfection0medium41
HIV Infections0medium41
HIV Seroconversion0low10
HIV Seropositivity0low10
HNSCC0low10
Hormone Refractory Prostatic Cancer0low10
Hormone Refractory Prostatic Neoplasms0low10
HPV Infection0medium21
HTLV-III Infections0medium41
HTLV-III Seroconversion0low10
HTLV-III Seropositivity0low10
HTLV-III-LAV Infections0medium41
Human Babesiosis0low40
Human Flu0low30
Human Herpes Virus 4 Infections0low10
Human Herpesvirus 4 Infections0low10
Human Influenza0low30
Human Mammary Carcinoma0medium204
Human Papillomavirus Infection0medium21
Hydatid Cyst, Hepatic0low10
Hydatidosis, Hepatic0low10
Hydrophobia0low20
Hydrops0low10
Hyperalgesia0low20
Hyperalgesia, Mechanical0low20
Hyperalgesia, Primary0low20
Hyperalgesia, Secondary0low20
Hyperalgesia, Tactile0low20
Hyperalgesia, Thermal0low20
Hyperalgesic Sensations0low20
Hyperalgia0low20
Hyperalgia, Mechanical0low20
Hyperalgia, Primary0low20
Hyperalgia, Secondary0low20
Hypercholesteremia0low10
Hypercholesterolemia0low10
Hypercytokinemia0low10
Hyperglycemia0low20
Hyperglycemia, Postprandial0low20
Hyperlipemia0low20
Hyperlipidemia0low20
Hyperlipidemias0low20
Hypernephroma0low10
Hyperoxia0low10
Hypersensitivity0low20
Hypersensitivity, Delayed0low40
Hypersensitivity, Drug0low10
Hypersensitivity, Tuberculin-Type0low40
Hypersensitivity, Type IV0low40
Hypoacusis0low10
Hypocalcemia0low10
Hypoglycemia0low20
Hypopharyngeal Squamous Cell Carcinoma0low10
Hypotensive Transfusion Reaction0low30
Hypovolemic Shock0low30
Hypoxemia0low10
Hypoxia0low10
Hypoxia-Ischemia, Brain0low10
Hypoxia-Ischemia, Cerebral0low10
Hypoxic-Ischemic Encephalopathy0low10
Icterus0medium11
IDDM0low40
Idiopathic Autoimmune Hemolytic Anemia0low30
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low30
Idiopathic Fibrosing Alveolitis, Chronic Form0low10
Idiopathic Proctocolitis0low30
Idiopathic Pulmonary Fibrosis0low10
Idiopathic Pulmonary Fibrosis, Familial0low10
IGA Glomerulonephritis0medium21
IGA Nephropathy0medium21
Iga Nephropathy 10medium21
IgA Vasculitis0low10
Immune Diseases0low10
Immune Disorders0low10
Immune System Diseases0low10
Immune System Disorders0low10
Immunoglobulin A Nephropathy0medium21
Immunologic Diseases0low10
Immunological Diseases0low10
Imported Diseases, Infectious0low10
Imported Infections0low10
Imported Infectious Diseases0low10
Inapparent Infections0low10
Inclusion Disease0medium141
Incoordination0low20
Infant, Newborn, Diseases0low10
Infant, Premature, Diseases0low10
Infarct of the Spleen0low30
Infarction, Middle Cerebral Artery0low30
Infection Reactivation0medium21
Infection, Central Nervous System, Protozoal0low10
Infection, Postoperative Wound0low10
Infection, Surgical Wound0low10
Infection, Toxoplasma gondii0low10
Infections, Coronavirus0low20
Infections, Cytomegalovirus0medium141
Infections, E coli0low20
Infections, EBV0low10
Infections, Epstein-Barr Virus0low10
Infections, Escherichia coli0low20
Infections, Gram-Negative Bacterial0low10
Infections, Helicobacter0low20
Infections, Herpesviridae0low20
Infections, Herpesvirus0low20
Infections, Plasmodium0medium37761
Infections, Protozoal, Central Nervous System0low10
Infections, Pseudomonas0low10
Infections, Respiratory0medium11
Infections, Respiratory Tract0medium11
Infections, Roseolovirus0low10
Infections, Staphylococcal0low30
Infections, Trematode0medium21
Infections, Upper Respiratory0medium11
Infections, Upper Respiratory Tract0medium11
Infectious Diseases0low10
Infectious Diseases, Emerging0low10
Infectious Diseases, Re-Emerging0low10
Infectious Diseases, Reemerging0low10
Infectious Mononucleosis-Like Syndrome, Chronic0low10
Infectious Pregnancy Complications0medium102
Inflammation0low180
Inflammatory Bowel Disease, Ulcerative Colitis Type0low30
Influenza0low30
Influenza in Humans0low30
Influenza, Human0low30
Injuries0low10
Injuries and Wounds0low10
Injuries, Acute Brain0low10
Injuries, Brain0low10
Injuries, Foot0low10
Injuries, Knee0low10
Injuries, Wounds0low10
Injury, Ischemia-Reperfusion0low50
Injury, Reperfusion0low50
Innate Inflammatory Response0low180
Insulin-Dependent Diabetes Mellitus 10low40
Intention Tremor0low10
Intermittent Tremor0low10
Interstitial Nephritis0low10
Interstitial Pneumonitis, Usual0low10
Intestinal Diseases0low10
Intestinal Diseases, Parasitic0low10
Intracerebral Hemorrhage0low10
Intracranial Central Nervous System Disorders0low30
Intracranial CNS Disorders0low30
Intracranial Edema0low10
Intracranial Neoplasms0low80
Intracranial Vascular Disorders0low10
Intraepithelial Neoplasms0low10
Intrahepatic Cholangiocarcinoma0low10
Intravascular Coagulation, Disseminated0low30
Intravascular Disseminated Coagulation0low30
Intravascular Hemolysis0medium384
Invasive Ductal Carcinoma, Breast0low10
Invasiveness, Neoplasm0medium81
Involuntary Quiver0low10
Iodamoebiasis0low10
Iron Overload0low30
Iron-Deficiency Anemia0low10
Iron-Deficiency Anemias0low10
Irvine-Gass Syndrome0low10
Ischemia0low10
Ischemia-Anoxia, Brain0low10
Ischemia-Anoxia, Cerebral0low10
Ischemia-Hypoxia, Brain0low10
Ischemia-Hypoxia, Cerebral0low10
Ischemia-Reperfusion Injury0low50
Ischemia, Cerebral0low20
Ischemic Encephalopathy0low20
Ischemic-Hypoxic Encephalopathy0low10
Itching0medium11
Jacksonian Seizure0low10
Jaundice0medium11
Jaundice, Hemolytic0medium11
JC Polyomavirus Encephalopathy0low10
Joint Diseases0low10
Junctional Epidermolysis Bullosa0low10
Juvenile-Onset Diabetes0low40
Kahler Disease0low60
Kala-Azar0medium51
Kaposi Sarcoma0low10
Kaposi's Sarcoma0low10
Katayama Fever0medium102
Keloid0low10
Keskushermoston sairaudet@fi0medium21
Kidney Cancer0low20
Kidney Diseases0low10
Kidney Failure0low20
Kidney Failure, Acute0medium131
Kidney Insufficiency0low20
Kidney Insufficiency, Acute0medium131
Kidney Neoplasms0low20
Kidney Scarring0low10
Knee Injuries0low10
Lack of Coordination0low20
Lactic Acidosis0medium11
Large Lymphoid Lymphoma, Diffuse0low20
Large-Cell Lymphoma, Diffuse0low20
Laryngeal Squamous Cell Carcinoma0low10
Late Effects, Prenatal Exposure0medium51
Late Onset Alzheimer Disease0low30
Left Middle Cerebral Artery Infarction0low30
Left Ventricular Dysfunction0low10
Left-Sided Heart Failure0low10
Leishmaniasis, American0medium31
Leishmaniasis, Cutaneous0medium31
Leishmaniasis, New World0medium31
Leishmaniasis, Old World0medium31
Leishmaniasis, Visceral0medium51
Lenticulostriate Disorders0low10
Leptospira Canicola Infection0low10
Leptospira Infection0low10
Leptospirosis0low10
Leptospirosis Canicola0low10
Lethal Junctional Epidermolysis Bullosa0low10
Leucocythaemia0low80
Leucocythemia0low80
Leukemia0low80
Leukemia, Acute Lymphoblastic0low10
Leukemia, Acute Myelogenous0low90
Leukemia, Acute Myeloid0low90
Leukemia, B Cell, Chronic0low10
Leukemia, B-Cell, Chronic0low10
Leukemia, Chronic Lymphatic0low10
Leukemia, Chronic Lymphocytic0low10
Leukemia, Chronic Lymphocytic, B-Cell0low10
Leukemia, Chronic Myelogenous0low10
Leukemia, Chronic Myeloid0low10
Leukemia, Granulocytic, Chronic0low10
Leukemia, Lymphoblastic0low10
Leukemia, Lymphoblastic, Acute0low10
Leukemia, Lymphoblastic, Acute, L10low10
Leukemia, Lymphoblastic, Acute, L20low10
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive0low10
Leukemia, Lymphoblastic, Burkitt-Type0low20
Leukemia, Lymphoblastic, Chronic0low10
Leukemia, Lymphocytic, Acute0low10
Leukemia, Lymphocytic, Acute, L10low10
Leukemia, Lymphocytic, Acute, L20low10
Leukemia, Lymphocytic, Chronic0low10
Leukemia, Lymphocytic, Chronic, B Cell0low10
Leukemia, Lymphocytic, Chronic, B-Cell0low10
Leukemia, Lymphocytic, L30low20
Leukemia, Lymphoid, Acute0low10
Leukemia, Myeloblastic, Acute0low90
Leukemia, Myelocytic, Acute0low90
Leukemia, Myelocytic, Chronic0low10
Leukemia, Myelogenous, Acute0low90
Leukemia, Myelogenous, Chronic0low10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0low10
Leukemia, Myelogenous, Ph1 Positive0low10
Leukemia, Myelogenous, Ph1-Positive0low10
Leukemia, Myeloid, Acute0low90
Leukemia, Myeloid, Acute, M10low90
Leukemia, Myeloid, Acute, M20low90
Leukemia, Myeloid, Chronic0low10
Leukemia, Myeloid, Ph1 Positive0low10
Leukemia, Myeloid, Ph1-Positive0low10
Leukemia, Myeloid, Philadelphia Positive0low10
Leukemia, Myeloid, Philadelphia-Positive0low10
Leukemia, Nonlymphoblastic, Acute0low90
Leukemia, Nonlymphocytic, Acute0low90
Leukocytopenia0medium11
Leukoencephalopathy, Progressive Multifocal0low10
Leukopenia0medium11
Libman-Sacks Disease0low40
Light-Headedness0low10
Lightheadedness0low10
Lipemia0low20
Lipidemia0low20
Liver Cancer0low160
Liver Cancer, Adult0low150
Liver Cell Carcinoma0low150
Liver Cell Carcinoma, Adult0low150
Liver Cirrhoses, Experimental0low20
Liver Cirrhosis0low60
Liver Cirrhosis, Experimental0low20
Liver Diseases0low20
Liver Dysfunction0low20
Liver Fibrosis0low60
Liver Injury, Drug-Induced0medium91
Liver Injury, Drug-Induced, Acute0medium91
Liver Injury, Drug-Induced, Chronic0low10
Liver Neoplasms0low160
Liver Neoplasms, Experimental0low40
Liver Steatosis0low10
Loa loa Filariasis0medium11
Loa loa Infection0medium11
Loaiasis0medium11
Lobar Pneumonia0low10
Local Neoplasm Recurrence0medium41
Local Neoplasm Recurrences0medium41
Locoregional Neoplasm Recurrence0medium41
Loiasis0medium11
Long QT Syndrome0medium21
Lung Adenocarcinoma0low20
Lung Cancer0medium221
Lung Inflammation0low10
Lung Injuries0low30
Lung Injury0low30
Lung Injury, Acute0low80
Lung Neoplasms0medium221
Lupus Erythematosus Disseminatus0low40
Lupus Erythematosus, Systemic0low40
Lupus Glomerulonephritis0low10
Lupus Nephritis0low10
Lyme Arthritis0low10
Lyme Borreliosis0low10
Lyme Disease0low10
Lymphatic Diseases0low10
Lymphatic Sarcoma0low10
Lymphatism0low10
Lymphoblastic Leukemia0low10
Lymphoblastic Leukemia, Acute0low10
Lymphoblastic Leukemia, Acute, Adult0low10
Lymphoblastic Leukemia, Acute, Childhood0low10
Lymphoblastic Leukemia, Acute, L10low10
Lymphoblastic Leukemia, Acute, L20low10
Lymphoblastic Leukemia, Chronic0low10
Lymphoblastic Lymphoma0low10
Lymphocytic Leukemia, Acute0low10
Lymphocytic Leukemia, Chronic0low10
Lymphocytic Leukemia, Chronic, B Cell0low10
Lymphocytic Leukemia, Chronic, B-Cell0low10
Lymphocytic Leukemia, L10low10
Lymphocytic Leukemia, L20low10
Lymphocytic Leukemia, L30low20
Lymphocytic Lymphoma0low10
Lymphocytic Lymphoma, Diffuse, Well Differentiated0low10
Lymphocytic Lymphoma, Diffuse, Well-Differentiated0low10
Lymphocytic Lymphoma, Well Differentiated0low10
Lymphocytic Lymphoma, Well-Differentiated0low10
Lymphohistiocytosis, Hemophagocytic0low30
Lymphoma0low20
Lymphoma, Atypical Diffuse Small Lymphoid0low10
Lymphoma, B-Cell0low20
Lymphoma, Burkitt0low20
Lymphoma, Diffuse0low10
Lymphoma, Diffuse Large-Cell0low20
Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, High-Grade0low10
Lymphoma, Histiocytic0low20
Lymphoma, Histiocytic, Diffuse0low20
Lymphoma, Intermediate-Grade0low10
Lymphoma, Large B-Cell, Diffuse0low20
Lymphoma, Large Cell, Diffuse0low20
Lymphoma, Large Lymphoid, Diffuse0low20
Lymphoma, Large-Cell, Diffuse0low20
Lymphoma, Low-Grade0low10
Lymphoma, Lymphoblastic0low10
Lymphoma, Lymphocytic0low10
Lymphoma, Lymphocytic, Diffuse, Well Differentiated0low10
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated0low10
Lymphoma, Lymphocytic, Well Differentiated0low10
Lymphoma, Lymphocytic, Well-Differentiated0low10
Lymphoma, Lymphoplasmacytoid, CLL0low10
Lymphoma, Malignant0low20
Lymphoma, Mixed0low10
Lymphoma, Mixed Cell, Diffuse0low10
Lymphoma, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Mixed Small and Large Cell, Diffuse0low10
Lymphoma, Mixed-Cell0low10
Lymphoma, Mixed-Cell, Diffuse0low10
Lymphoma, Non-Hodgkin0low10
Lymphoma, Non-Hodgkin, Familial0low10
Lymphoma, Non-Hodgkin's0low10
Lymphoma, Non-Hodgkins0low10
Lymphoma, Nonhodgkin's0low10
Lymphoma, Nonhodgkins0low10
Lymphoma, Pleomorphic0low10
Lymphoma, Primary Effusion0low10
Lymphoma, Small and Large Cleaved-Cell, Diffuse0low10
Lymphoma, Small Cleaved Cell, Diffuse0low10
Lymphoma, Small Cleaved-Cell, Diffuse0low10
Lymphoma, Small Lymphocytic0low10
Lymphoma, Small Lymphocytic, Plasmacytoid0low10
Lymphoma, Small Non-Cleaved-Cell0low10
Lymphoma, Small Noncleaved-Cell0low10
Lymphoma, Small-Cell0low10
Lymphoma, Undifferentiated0low10
Lymphoma, Undifferentiated, Diffuse0low10
Lymphoplasmacytoid Lymphoma, CLL0low10
Lymphosarcoma0low10
Lyssa0low20
Macular Dystrophy, Dominant Cystoid0low10
Macular Edema0low10
Macular Edema, Cystoid0low10
Maladie du systu00E8me nerveux central@fr0medium21
Malaria0medium37761
Malaria Meningitis0medium6512
Malaria, Avian0medium42
Malaria, Cerebral0medium6512
Malaria, Falciparum0medium736288
Malaria, Hemolytic0low20
Malaria, Vivax0medium7821
Malattie del sistema nervoso centrale@it0medium21
Malignancy0medium311
Malignant Epithelial Neoplasms0low40
Malignant Glioma0low30
Malignant Histiocytosis0low10
Malignant Melanoma0low30
Malignant Neoplasm of Breast0medium204
Malignant Neoplasms0medium311
Malignant Neoplasms, Brain0low80
Malignant Primary Brain Neoplasms0low80
Malignant Primary Brain Tumors0low80
Malignant Tumor of Breast0medium204
Malignant Tumor of Urinary Bladder0low40
Malnourishment0low10
Malnutrition0low10
Mammary Cancer0medium204
Mammary Carcinoma, Animal0low10
Mammary Carcinoma, Human0medium204
Mammary Ductal Carcinoma0low10
Mammary Neoplasm, Human0medium204
Mammary Neoplasms0low10
Mammary Neoplasms, Animal0low10
Mammary Neoplasms, Experimental0low10
Mammary Neoplasms, Human0medium204
Marek Disease0low10
Marek's Disease0low10
Marsh Fever0medium37761
Massive Tremor0low10
Maternal Sepsis0medium102
MCA Infarct0low30
MCA Infarction0low30
Mechanical Allodynia0low20
Mechanical Hyperalgesia0low20
Melanoma0low30
Melanoma, B160low10
Melanoma, Cloudman S910low10
Melanoma, Experimental0low10
Melanoma, Harding-Passey0low10
Melanomas, Experimental0low10
Memory Deficits0low10
Memory Disorder, Semantic0low10
Memory Disorder, Spatial0low10
Memory Disorders0low10
Memory Disorders, Age-Related0low10
Memory Loss0low10
Meningoencephalitis0low10
Meningoencephalitis, Herpes Simplex Virus0low10
Meningoencephalitis, Protozoal0low10
Mental Disorders0medium11
Mental Disorders, Severe0medium11
Mental Illness0medium11
MERS (Middle East Respiratory Syndrome)0low20
Metabolic Acidosis0low10
Metagonimiasis0medium21
Metastase0medium72
Metastases, Neoplasm0medium72
Metastasis0medium72
Metastasis, Neoplasm0medium72
Microangiopathic Hemolytic Anemia0medium262
Micronuclei, Chromosome-Defective0low10
Micronuclei, Genotoxicant-Induced0low10
Micronucleus, Chromosome-Defective0low10
Middle Cerebral Artery Circulation Infarction0low30
Middle Cerebral Artery Embolic Infarction0low30
Middle Cerebral Artery Embolus0low30
Middle Cerebral Artery Infarction0low30
Middle Cerebral Artery Occlusion0low30
Middle Cerebral Artery Stroke0low30
Middle Cerebral Artery Syndrome0low30
Middle Cerebral Artery Thrombosis0low30
Middle Cerebral Artery Thrombotic Infarction0low30
Middle East Respiratory Syndrome0low20
Mixed Glioma0low30
Mixed Infection0low70
Mixed Small and Large Cell Lymphoma, Diffuse0low10
Mixed-Cell Lymphoma0low10
Mixed-Cell Lymphoma, Diffuse0low10
MODS0low40
Molluscum Fibrosum0low10
Moniliasis0low10
Monkey Diseases0low10
Mononeuropathy, Diabetic0low10
Mouth Cancer0low10
Mouth Neoplasms0low10
Mud Fever0low10
Multiple Idiopathic Pigmented Hemangiosarcoma0low10
Multiple Myeloma0low60
Multiple Organ Dysfunction Syndrome0low40
Multiple Organ Failure0low40
Muscle Relaxation0low20
Muscle Weakness0medium11
Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis0low10
Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis0low10
Muscular Weakness0medium11
Musculoskeletal Abnormalities0low10
MuSK MG0low10
MuSK Myasthenia Gravis0low10
Myalgic Encephalomyelitis0low10
Myasthenia Gravis0low10
Myasthenia Gravis, Autoimmune Experimental0low10
Myasthenia Gravis, Autoimmune, Experimental0low10
Myasthenia Gravis, Experimental Autoimmune0low10
Myasthenia Gravis, Generalized0low10
Myasthenia Gravis, Ocular0low10
Myeloblastic Leukemia, Acute0low90
Myelocytic Leukemia, Acute0low90
Myelocytic Leukemia, Chronic0low10
Myelodysplastic Syndromes0low10
Myelogenous Leukemia, Acute0low90
Myelogenous Leukemia, Chronic0low10
Myelogenous Leukemia, Ph1-Positive0low10
Myeloid Leukemia, Acute0low90
Myeloid Leukemia, Acute, M10low90
Myeloid Leukemia, Acute, M20low90
Myeloid Leukemia, Chronic0low10
Myeloid Leukemia, Ph1-Positive0low10
Myeloid Leukemia, Philadelphia-Positive0low10
Myeloma-Multiple0low60
Myeloma, Multiple0low60
Myeloma, Plasma-Cell0low60
Myelomatosis0low60
Myh-Associated Polyposis0low10
Myocardial Failure0low10
Myocardial Infarct0low10
Myocardial Infarction0low10
Myocarditis0low20
Myoclonic Seizure0low10
Myoclonic Seizures0low10
Naegleria fowleri Infection0low10
Naegleria fowleri Meningoencephalitis0low10
NAFLD0low10
Nasopharyngeal Cancer0low10
Nasopharyngeal Carcinoma0low10
Nasopharyngeal Neoplasms0low10
Nasopharynx Cancer0low10
Nasopharynx Neoplasms0low10
Nausea0medium54
Neck Cancer0low20
Neck Neoplasm0low20
Neck Neoplasms0low20
Necrosis0low40
Neglected Diseases0low10
nemoci centru00E1lnu00EDho nervovu00E9ho systu00E9mu@cs0medium21
Neonatal Death0low10
Neonatal Diseases0low10
Neoplasia0medium311
Neoplasm0medium311
Neoplasm Invasion0medium81
Neoplasm Invasiveness0medium81
Neoplasm Metastases0medium72
Neoplasm Metastasis0medium72
Neoplasm Recurrence, Local0medium41
Neoplasm Recurrence, Locoregional0medium41
Neoplasm Recurrences, Local0medium41
Neoplasms0medium311
Neoplasms, Benign0medium311
Neoplasms, Bile Duct0low10
Neoplasms, Bladder0low40
Neoplasms, Bone0low20
Neoplasms, Brain0low80
Neoplasms, Brain, Benign0low80
Neoplasms, Brain, Malignant0low80
Neoplasms, Brain, Primary0low80
Neoplasms, Breast0medium204
Neoplasms, Central Nervous System0low10
Neoplasms, Cervical0medium51
Neoplasms, Cervix0medium51
Neoplasms, Colonic0low70
Neoplasms, Colorectal0medium91
Neoplasms, Endometrial0low20
Neoplasms, Esophageal0low30
Neoplasms, Experimental0low30
Neoplasms, Experimental Liver0low40
Neoplasms, Experimental Mammary0low10
Neoplasms, Gastric0low30
Neoplasms, Head0low20
Neoplasms, Head and Neck0low20
Neoplasms, Hepatic0low160
Neoplasms, Intracranial0low80
Neoplasms, Intraepithelial0low10
Neoplasms, Kidney0low20
Neoplasms, Liver0low160
Neoplasms, Lung0medium221
Neoplasms, Malignant Epithelial0low40
Neoplasms, Mammary0low10
Neoplasms, Mouth0low10
Neoplasms, Nasopharyngeal0low10
Neoplasms, Neck0low20
Neoplasms, Oral0low10
Neoplasms, Ovarian0low90
Neoplasms, Pancreatic0low40
Neoplasms, Prostate0low50
Neoplasms, Prostatic0low50
Neoplasms, Pulmonary0medium221
Neoplasms, Retinal0low10
Neoplasms, Skin0low30
Neoplasms, Stomach0low30
Neoplasms, Thyroid0low10
Neoplasms, Tongue0low20
Neoplasms, Upper Aerodigestive Tract0low20
Neoplasms, Vulvar0low10
Neoplastic Cell Transformation0low20
Neoplastic Transformation, Cell0low20
Neovascularization, Choroid0low10
Neovascularization, Choroidal0low10
Neovascularization, Optic Disc0low20
Neovascularization, Pathologic0low90
Neovascularization, Pathological0low90
Neovascularization, Retinal0low20
Nephritis0low20
Nephritis, IGA Type0medium21
Nephritis, Interstitial0low10
Nephritis, Lupus0low10
Nephritis, Tubulointerstitial0low10
Nephroid Carcinoma0low10
Nephropathy, IGA0medium21
Nervous System Degenerative Diseases0low10
Nervous System Diseases0medium42
Nervous System Disorders0medium42
Neuralgia, Diabetic0low10
Neurilemmoma0low10
Neurilemoma0low10
Neurinoma0low10
Neuroblastoma0low10
Neuroblastoma, Retinal0low20
Neurocoenurosis0low10
Neurocysticercosis0low10
Neurodegenerative Diseases0low10
Neurodegenerative Disorders0low10
Neurodermatitis, Atopic0low10
Neurodermatitis, Disseminated0low10
Neuroendocrine Tumors0low10
Neurofibromatosis 10low10
Neurofibromatosis I0low10
Neurofibromatosis Type 10low10
Neurofibromatosis Type I0low10
Neurofibromatosis, Peripheral Type0low10
Neurofibromatosis, Peripheral, NF 10low10
Neurofibromatosis, Peripheral, NF10low10
Neurofibromatosis, Type 10low10
Neurofibromatosis, Type I0low10
Neurologic Degenerative Conditions0low10
Neurologic Degenerative Diseases0low10
Neurologic Diseases, Degenerative0low10
Neurologic Disorders0medium42
Neurological Disorders0medium42
Neuropapillitis0low10
Neutropenia0medium52
NF1 (Neurofibromatosis 1)0low10
Non-alcoholic Fatty Liver Disease0low10
Non-Epileptic Seizure0low10
Non-Epileptic Seizures0low10
Non-Hodgkin Lymphoma0low10
Non-Hodgkin's Lymphoma0low10
Non-Small Cell Lung Cancer0medium131
Non-Small Cell Lung Carcinoma0medium131
Non-Small-Cell Lung Carcinoma0medium131
Nonalcoholic Fatty Liver Disease0low10
Nonalcoholic Steatohepatitis0low10
Nonepileptic Seizure0low10
Nonepileptic Seizures0low10
Nonlymphoblastic Leukemia, Acute0low90
Nonlymphocytic Leukemia, Acute0low90
Nonsmall Cell Lung Cancer0medium131
Nutritional Deficiency0low10
Occlusion, Middle Cerebral Artery0low30
Ocular Headache0medium22
Ocular Rosacea0low10
Oesophageal Squamous Cell Carcinoma0low10
Oliguria0low10
Oncogenesis0low30
Opisthorchiasis0medium11
Opisthorchis felineus Infection0medium11
Opisthorchis Infection0medium11
Opisthorchis sinensis Infection0low70
Opisthorchis viverrini Infection0medium11
Optic Disc Neovascularization0low20
Optic Disk Neovascularization0low20
Optic Neuritis0low10
Oral Cancer0low10
Oral Cavity Squamous Cell Carcinoma0low10
Oral Neoplasms0low10
Oral Squamous Cell Carcinoma0low10
Oral Squamous Cell Carcinomas0low10
Oral Tongue Squamous Cell Carcinoma0low10
Organ Dysfunction Syndrome, Multiple0low40
Organ Failure, Multiple0low40
Oriental Sore0medium31
Orientia tsutsugamushi Infection0low20
Oropharyngeal Squamous Cell Carcinoma0low10
Orphan Diseases0low20
Orthostasis0low10
Orthostatic Headache0medium22
Osteoarthritis0low60
Osteoarthrosis0low60
Osteoarthrosis Deformans0low60
Osteoclastic Bone Loss0low20
Osteogenic Sarcoma0low20
Osteolysis0low10
Osteoporosis0low70
Osteoporosis, Age-Related0low70
Osteoporosis, Involutional0low70
Osteoporosis, Post-Traumatic0low70
Osteoporosis, Senile0low70
Osteosarcoma0low20
Osteosarcoma Tumor0low20
Ovarian Cancer0low90
Ovarian Cancer, Epithelial0low10
Ovarian Epithelial Cancer0low10
Ovarian Epithelial Carcinoma0low10
Ovarian Neoplasms0low90
Ovary Cancer0low90
Ovary Neoplasms0low90
Ovine Diseases0low30
Oxygen Deficiency0low10
Pain0low20
Pain, Burning0low20
Pain, Crushing0low20
Pain, Migratory0low20
Pain, Radiating0low20
Pain, Splitting0low20
Palmoplantaris Pustulosis0low10
Paludism0medium37761
Pancreas Cancer0low40
Pancreas Neoplasms0low40
Pancreatic Cancer0low40
Pancreatic Neoplasms0low40
Pancreatic Parenchyma with Edema0low30
Pancreatic Parenchymal Edema0low30
Pancreatitis0low30
Pancreatitis, Acute0low30
Pancreatitis, Acute Edematous0low30
Pancytopenia0low30
Papillary Renal Cell Carcinoma0low10
Papillomavirus Infections0medium21
Papulopustular Rosacea0low10
Parasite Infections0low10
Parasitemia0medium14657
Parasitic Diseases0low10
Parasitic Diseases, Animal0low10
Parasitic Infections0low10
Parasitic Infections, Animal0low10
Parasitic Intestinal Diseases0low10
Parasitic Pregnancy Complications0medium2211
Paroxysmal Dyskinesias0low10
Partial Seizure0low10
Partial Seizures0low10
Passive Transfer Experimental Autoimmune Myasthenia Gravis0low10
Passive Tremor0low10
Pathologic Angiogenesis0low90
Pathologic Neovascularization0low90
Pediatric Respiratory Distress Syndrome0low60
Pericementitis0low30
Perinatal Death0low10
Perinatal Subarachnoid Hemorrhage0low10
Periodontal Bone Loss0low20
Periodontal Resorption0low20
Periodontitis0low30
Periorbital Headache0medium22
Peripancreatic Fat Necrosis0low30
Peripheral Neurofibromatosis0low10
Persistent Tremor0low10
Petit Mal Convulsion0low10
Phymatous Rosacea0low10
Pill Rolling Tremor0low10
Piroplasmosis0low40
Pituitary Adenoma0low10
Pituitary Cancer0low10
Pituitary Carcinoma0low10
Pituitary Neoplasms0low10
Pituitary Tumors0low10
Plaque, Atherosclerotic0low20
Plasma Cell Myeloma0low60
Plasmodium falciparum Malaria0medium736288
Plasmodium Infections0medium37761
Plasmodium vivax Malaria0medium7821
Pleural Effusion0low10
Pneumonia0low10
Pneumonia, Lobar0low10
Pneumonia, Viral0low40
Pneumonitis0low10
Poisoning, Blood0medium101
Polymicrobial Infection0low70
Polyposis Coli0low10
Polyposis Coli, Familial0low10
Polyposis Syndrome, Familial0low10
Polyposis, Adenomatous Intestinal0low10
Portal-Systemic Encephalopathy0low10
Portosystemic Encephalopathy0low10
Positional Vertigo0medium22
Post-Transfusion Purpura0low30
Postabsorptive Hypoglycemia0low20
Posterior Optic Neuritis0low10
Postoperative Complications0low10
Postoperative Wound Infection0low10
Postprandial Hyperglycemia0low20
Postprandial Hypoglycemia0low20
Posttransfusion Purpura0low30
Postviral Fatigue Syndrome0low10
Poultry Diseases0medium32
Pre-Symptomatic Diseases0low10
Precursor Cell Lymphoblastic Leukemia-Lymphoma0low10
Pregnancy0medium6918
Pregnancy Complications, Infectious0medium102
Pregnancy Complications, Parasitic0medium2211
Pregnancy, Infectious Complications0medium102
Pregnancy, Parasitic Complications0medium2211
Premature Birth0medium21
Prenatal Exposure Delayed Effects0medium51
Presenile Alzheimer Dementia0low30
Presymptomatic Diseases0low10
Presymptomatic Infections0low10
Preterm Birth0medium21
Primary Amebic Meningoencephalitis0low10
Primary Brain Neoplasms0low80
Primary Central Nervous System Neoplasm0low10
Primary Central Nervous System Neoplasms0low10
Primary Effusion Lymphoma0low10
Primary Hemophagocytic Hymphohistiocytosis0low30
Primary Hemophagocytic Lymphohistiocytosis0low30
Primary Malignant Brain Neoplasms0low80
Primary Malignant Brain Tumors0low80
Primary Senile Degenerative Dementia0low30
Progressive Multifocal Leukoencephalopathy0low10
Proliferative Vitreoretinopathy0low10
Prostate Cancer0low50
Prostate Neoplasms0low50
Prostatic Cancer0low50
Prostatic Cancer, Androgen-Independent0low10
Prostatic Cancer, Androgen-Insensitive0low10
Prostatic Cancer, Androgen-Resistant0low10
Prostatic Cancer, Castration-Resistant0low10
Prostatic Cancer, Hormone Refractory0low10
Prostatic Neoplasms0low50
Prostatic Neoplasms, Androgen-Independent0low10
Prostatic Neoplasms, Androgen-Insensitive0low10
Prostatic Neoplasms, Androgen-Resistant0low10
Prostatic Neoplasms, Castration-Resistant0low10
Prostatic Neoplasms, Hormone Refractory0low10
Proteinuria0medium31
Protozoal Infections, Central Nervous System0low10
Protozoal Infections, Cerebral0low10
Protozoal Meningoencephalitis0low10
Pruritis0medium11
Pruritus0medium11
Pseudocoma0medium32
Pseudomonas aeruginosa Infection0low10
Pseudomonas Infections0low10
Psoriasis0low10
Psychiatric Diagnosis0medium11
Psychiatric Diseases0medium11
Psychiatric Disorders0medium11
Psychiatric Illness0medium11
Psychoses0low10
Psychosis0low10
Psychosis, Brief Reactive0low10
Psychotic Disorders0low10
Pulmonary Cancer0medium221
Pulmonary Disease, Chronic Obstructive0low40
Pulmonary Edema0low10
Pulmonary Edemas0low10
Pulmonary Fibroses0low30
Pulmonary Fibrosis0low30
Pulmonary Fibrosis, Idiopathic0low10
Pulmonary Inflammation0low10
Pulmonary Injury0low30
Pulmonary Neoplasms0medium221
Pulmonic Stenosis with Cafe-au-Lait Spots0low10
Pulseless Disease0low10
Purpura Fulminans0low20
Pustular Psoriasis of Palms and Soles0low10
Pustulosis of Palms and Soles0low10
Pustulosis Palmaris et Plantaris0low10
Pyaemia0medium101
Pyemia0medium101
Pyohemia0medium101
Pyrexia0medium3118
Rabies0low20
Rare Diseases0low20
Rash0low10
Re-infection0medium21
Reactivated Infection0medium21
Reactive Hemophagocytic Syndrome0low30
Reactive Hypoglycemia0low20
Recklinghausen Disease of Nerve0low10
Recklinghausen Disease, Nerve0low10
Recklinghausen's Disease of Nerve0low10
Recklinghausens Disease of Nerve0low10
Recrudescence0medium5128
Recurrence0medium5128
Recurrence, Local Neoplasm0medium41
Recurrence, Locoregional Neoplasm0medium41
Recurrences, Local Neoplasm0medium41
Recurrent Infection0medium21
Reinfection0medium21
Relapse0medium5128
Remittent Fever0medium37761
Renal Cancer0low20
Renal Carcinoma0low10
Renal Cell Cancer0low10
Renal Cell Carcinoma0low10
Renal Cell Carcinoma, Papillary0low10
Renal Collecting Duct Carcinoma0low10
Renal Failure0low20
Renal Failure, Acute0medium131
Renal Insufficiency0low20
Renal Insufficiency, Acute0medium131
Renal Neoplasms0low20
Reperfusion Damage0low50
Reperfusion Injury0low50
Research-Related Injuries0low10
Resistance, Disease0low10
Respiratory Distress Syndrome0low60
Respiratory Distress Syndrome, Acute0low60
Respiratory Distress Syndrome, Adult0low60
Respiratory Distress Syndrome, Pediatric0low60
Respiratory Infections0medium11
Respiratory Tract Diseases0low10
Respiratory Tract Infections0medium11
Rest Tremor0low10
Resting Tremor0low10
Retention Disorders, Cognitive0low10
Reticulolymphosarcoma0low20
Reticulosarcoma0low10
Reticulosis, Familial Histiocytic0low30
Reticulum Cell Sarcoma0low10
Reticulum-Cell Sarcoma0low10
Retinal Cancer0low10
Retinal Neoplasms0low10
Retinal Neovascularization0low20
Retinal Tumors0low10
Retinoblastoma0low20
Retro-Ocular Headache0medium22
Retrobulbar Neuritis0low10
Rhabdomyosarcoma, Embryonal0low10
Rheumatic Chorea0low10
Rheumatoid Arthritis0low100
Rhinolalia0low10
Rice-Field Fever0low10
Right Middle Cerebral Artery Infarction0low30
Right-Sided Heart Failure0low10
Rodent Diseases0low30
Rosacea0low10
Roseolovirus Infections0low10
Royal Free Disease0low10
SAH (Subarachnoid Hemorrhage)0low10
Salivary Gland Virus Disease0medium141
Salmonella typhi Infection0low10
Sappinia diploidea Meningoencephalitis0low10
Sarcoma, Germinoblastic0low20
Sarcoma, Kaposi0low10
Sarcoma, Lymphatic0low10
Sarcoma, Osteogenic0low20
Sarcoma, Reticulum-Cell0low10
Sarcomatoid Renal Cell Carcinoma0low10
SARS Coronavirus 2 Infection0medium92
SARS-CoV-2 Infection0medium92
Saturnine Tremor0low10
Scar0low20
Scarring0low20
Scars0low20
Scars, Hypertrophic0low40
Schistoma Infection0medium102
Schistosoma haematobia Infection0medium129
Schistosoma japonicum Infection0medium143
Schistosoma mansoni Infection0medium135
Schistosomiasis0medium102
Schistosomiasis haematobia0medium129
Schistosomiasis haematobium0medium129
Schistosomiasis japonica0medium143
Schistosomiasis japonicum0medium143
Schistosomiasis mansoni0medium135
Schistosomiasis, Intestinal0medium135
Schistosomiasis, Urinary0medium129
Schizoaffective Disorder0low10
Schizophreniform Disorders0low10
Schwannoma0low10
Schwannomatosis, Plexiform0low10
Scrub Typhus0low20
Sea Fan Neovascularization0low20
Secondary Infection0low70
Secondary Infections0low70
Seizure0low10
Seizure Disorder0low10
Seizures0low10
Seizures, Auditory0low10
Seizures, Clonic0low10
Seizures, Convulsive0low10
Seizures, Epileptic0low10
Seizures, Focal0low10
Seizures, Generalized0low10
Seizures, Gustatory0low10
Seizures, Motor0low10
Seizures, Olfactory0low10
Seizures, Sensory0low10
Seizures, Somatosensory0low10
Seizures, Tonic0low10
Seizures, Tonic-Clonic0low10
Seizures, Vertiginous0low10
Seizures, Vestibular0low10
Seizures, Visual0low10
Semantic Memory Disorder0low10
Senile Chorea0low10
Senile Dementia, Acute Confusional0low30
Senile Dementia, Alzheimer Type0low30
Senile Osteoporosis0low70
Senile Tremor0low10
Sensitivity and Specificity0low170
Sepsis0medium101
Sepsis during Pregnancy0medium102
Sepsis in Pregnancy0medium102
Septic Shock0low10
Septicemia0medium101
Severe Sepsis0medium101
Sharp Headache0medium22
Sheep Diseases0low30
Shock0low30
Shock Lung0low60
Shock, Anaphylactic0low20
Shock, Endotoxic0low10
Shock, Hemorrhagic0low20
Shock, Septic0low10
Shock, Toxic0low10
Sicca Syndrome0low20
Sickle Cell Anemia0low10
Sickle Cell Disease0low10
Sickle Cell Disorders0low10
Sickling Disorder Due to Hemoglobin S0low10
Side Effects of Drugs0medium136
Single Seizure0low10
Sjogren Syndrome0low20
Sjogren's Syndrome0low20
Skin Cancer0low30
Skin Neoplasms0low30
Skin Rash0low10
Small Airway Remodeling0low20
Small Airway Remodelling0low20
Small Cleaved-Cell Lymphoma, Diffuse0low10
Small Non-Cleaved-Cell Lymphoma0low10
Small Noncleaved-Cell Lymphoma0low10
Small-Cell Lymphoma0low10
Spasmophilia0low10
Spatial Memory Disorder0low10
Speech Disorders0low10
Spinning Sensation0medium22
Splenic Infarct0low30
Splenic Infarction0low30
Splenic Infarcts0low30
Splenomegaly0low10
Sporadic Retinoblastoma0low20
Squamous Cell Carcinoma0low60
Squamous Cell Carcinoma of Head and Neck0low10
Squamous Cell Carcinoma of Larynx0low10
Squamous Cell Carcinoma of the Head and Neck0low10
Squamous Cell Carcinoma of the Larynx0low10
Squamous Cell Carcinoma of the Mouth0low10
Squamous Cell Carcinoma of the Nasal Cavity0low10
Squamous Cell Carcinoma, Head And Neck0low10
SREDIu0160NJI u017DIVu010CANI SUSTAV, BOLESTI@hr0medium21
St. Vitus's Dance0low10
Staphylococcal Infections0low30
Staphylococcus aureus Infection0low30
Static Tremor0low10
Status Lymphaticus0low10
Steatohepatitis0low10
Steatosis of Liver0low10
Stillbirth0low10
Stomach Cancer0low30
Stomach Neoplasms0low30
Stomach Ulcer0low30
Streptozocin Diabetes0low60
Streptozotocin Diabetes0low60
Stroke0low20
Stroke, Acute0low20
Stroke, Middle Cerebral Artery0low30
Stuttgart Disease0low10
Subarachnoid Hemorrhage0low10
Subarachnoid Hemorrhage, Aneurysmal0low10
Subarachnoid Hemorrhage, Intracranial0low10
Subarachnoid Hemorrhage, Spontaneous0low10
Subclinical Infections0low10
Subdural Hematoma0low30
Subdural Hematoma, Acute0low10
Subdural Hematoma, Traumatic0low30
Suffering, Physical0low20
Surgery-Induced Tissue Adhesions0low10
Surgical Adhesions0low10
Surgical Site Infection0low10
Surgical Wound Infection0low10
Susceptibility, Disease0medium21
Swineherd's Disease0low10
Sydenham Chorea0low10
Sydenham's Chorea0low10
Sykdommer i sentralnervesystemet@no0medium21
Symmetric Diabetic Proximal Motor Neuropathy0low10
Symptom Cluster0low10
Syndrome0low10
Systemic Exertion Intolerance Disease0low10
Systemic Lupus Erythematosus0low40
T-Lymphotropic Virus Type III Infections, Human0medium41
Tactile Allodynia0low20
TAGHD0low30
Takayasu Arteritis0low10
Takayasu Disease0low10
Takayasu Syndrome0low10
Takayasu's Arteritis0low10
Tetanilla0low10
Tetany0low10
Tetany, Neonatal0low10
Thalassemia-alpha0medium21
Thermal Allodynia0low20
Thiamine Deficiency0medium11
Throbbing Headache0medium22
Thrombocytopenia0medium51
Thromboembolism, Venous0medium11
Thrombopenia0medium51
Thrombosis0low10
Thrombosis, Middle Cerebral Artery0low30
Thrombotic Infarction, Middle Cerebral Artery0low30
Thrombotic Microangiopathies0low10
Thrombus0low10
Thymoma0low10
Thyroid Adenoma0low10
Thyroid Cancer0low10
Thyroid Cancer, Anaplastic0low10
Thyroid Carcinoma0low10
Thyroid Carcinoma, Anaplastic0low10
Thyroid Neoplasms0low10
Tissue Adhesions0low10
Tongue Cancer0low20
Tongue Neoplasms0low20
Tonic Clonic Seizure0low10
Tonic Seizure0low10
Tonic Seizures0low10
Tonic-Clonic Seizure0low10
Tonic-Clonic Seizures0low10
Torsade de Pointes0medium11
Torsades de Pointes0medium11
Toxic Hepatitis0medium91
Toxic Shock0low10
Toxic Shock Syndrome0low10
Toxicity, Drug0medium136
Toxoplasma gondii Infection0low10
Toxoplasmosis0low10
Toxoplasmosis, Animal0low10
Transformation, Neoplastic Cell0low20
Transformation, Viral Cell0low10
Transfusion Reaction0low30
Transfusion-Associated Allergic Reaction0low30
Transfusion-Associated Circulatory Overload0low30
Transfusion-Associated Dyspnea0low30
Transfusion-Associated Graft Vs. Host Disease0low30
Transfusion-Transmitted Infection0low30
Transitory Hearing Loss0low10
Trauma0low10
Travel Sickness0low50
Travel-Associated Infections0low50
Travel-Associated Infectious Diseases0low50
Travel-Related Disease0low50
Travel-Related Health Problems0low50
Travel-Related Illness0low50
Travel-Related Infections0low50
Travel-Related Infectious Diseases0low50
Travel-Related Sickness0low50
Trematode Infections0medium21
Tremor0low10
Tremor, Limb0low10
Tremor, Muscle0low10
Tremor, Neonatal0low10
Tremor, Nerve0low10
Tremor, Perioral0low10
Tremor, Rubral0low20
Tremor, Semirhythmic0low10
Triple Negative Breast Cancer0low10
Triple Negative Breast Neoplasms0low10
Triple-Negative Breast Cancer0low10
Triple-Negative Breast Neoplasm0low10
True Histiocytic Lymphoma0low10
True Malignant Histiocytosis0low10
Trypanosoma cruzi Infection0low10
Trypanosomiasis0low10
Trypanosomiasis, South American0low10
Tsutsugamushi Disease0low20
Tsutsugamushi Fever0low20
Tuberculin-Type Hypersensitivity0low40
Tubulointerstitial Nephritis0low10
Tumorigenesis0low30
Tumorigenic Transformation0low20
Tumors0medium311
Tumors, Breast0medium204
Tumors, Central Nervous System0low10
Tumors, Retinal0low10
Turf Toe0low10
Type 1 Diabetes0low40
Type 1 Diabetes Mellitus0low40
Type IV Hypersensitivity0low40
Typhoid0low10
Typhoid Fever0low10
Typhus, Abdominal0low10
Typhus, Scrub0low20
u041Du0415u0420u0412u041Du041Eu0419 u0421u0418u0421u0422u0415u041Cu042B u0426u0415u041Du0422u0420u0410u041Bu042Cu041Du041Eu0419 u0411u041Eu041Bu0415u0417u041Du0418@ru0medium21
u4E2Du67A2u795Eu7D4Cu7CFBu75BEu60A3@ja0medium21
UADT Neoplasm0low20
UADT Neoplasms0low20
Ulcerative Colitis0low30
Undernutrition0low10
Undifferentiated Lymphoma0low10
Unilateral Headache0medium22
Upper Aerodigestive Tract Neoplasm0low20
Upper Aerodigestive Tract Neoplasms0low20
Upper Respiratory Infections0medium11
Upper Respiratory Tract Infection0medium11
Upper Respiratory Tract Infections0medium11
Ureteral Obstruction0low10
Urinary Bladder Cancer0low40
Urinary Bladder Neoplasms0low40
Urinary Schistosomiasis0medium129
Urogenital Schistosomiasis0medium129
Usual Interstitial Pneumonia0low10
Uterine Cervical Cancer0medium51
Uterine Cervical Dysplasia0medium11
Uterine Cervical Neoplasms0medium51
Uveal Neoplasms0low20
Uveitis, Anterior0low10
Vascular Accident, Brain0low20
Vascular Diseases0low10
Vascular Diseases, Intracranial0low10
Vasogenic Brain Edema0low10
Vasogenic Cerebral Edema0low10
Venous Thromboembolism0medium11
Ventricular Dysfunction, Left0low10
Verbal Fluency Disorders0low10
Vertex Headache0medium22
Vertigo0medium22
Vertigo, Brain Stem0medium22
Vertigo, Brainstem0medium22
Vertigo, Central Nervous System Origin0medium22
Vertigo, Central Origin0medium22
Vertigo, Constant0medium22
Vertigo, Essential0medium22
Vertigo, Intermittant0medium22
Vertigo, Paroxysmal0medium22
Vertigo, Peripheral0medium22
Vertigo, Subjective0medium22
Viral Cell Transformation0low10
Viremia0medium11
Visceral Steatosis0low10
Vitreoretinopathy Neovascular Inflammatory0low10
Vitreoretinopathy, Proliferative0low10
Vomiting0medium95
von Gierke Disease0medium11
von Gierke's Disease0medium11
von Recklinghausen Disease0low10
von Recklinghausen's Disease0low10
Vulva Cancer0low10
Vulva Neoplasms0low10
Vulvar Cancer0low10
Vulvar Neoplasms0low10
Watson Syndrome0low10
Wet Lung0low10
Wound Infection, Postoperative0low10
Wound Infection, Surgical0low10
Wounds0low10
Wounds and Injuries0low10
Wounds and Injury0low10
Wounds, Injury0low10
Young Female Arteritis0low10
Zentralnervensystemkrankheiten@de0medium21
Ziekte, centraalzenuwstelsel-@nl0medium21
Zoonoses0medium11
Zoonotic Diseases0medium11
Zoonotic Infections0medium11
Zoonotic Infectious Diseases0medium11
Zoonotic Spillover0medium11

Research Highlights

Safety/Toxicity (90)

ArticleYear
SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection.
Trials, Nov-27, Volume: 24, Issue: 1		2023
The update and transport of aluminum nanoparticles in plants and their biochemical and molecular phototoxicity on plant growth and development: A systematic review.
Environmental pollution (Barking, Essex : 1987), Jan-01, Volume: 340, Issue: Pt 1		2024
Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3.
Gynecologic oncology, Volume: 178		2023
Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar.
Parasite (Paris, France), Volume: 30		2023
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.
The Lancet. Global health, Volume: 11, Issue: 8		2023
Safety and efficacy of artesunate treatment in severely injured patients with traumatic hemorrhage. The TOP-ART randomized clinical trial.
Intensive care medicine, Volume: 49, Issue: 8		2023
Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals.
BMC infectious diseases, May-25, Volume: 23, Issue: 1		2023
Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Biomolecules, Oct-16, Volume: 12, Issue: 10		2022
Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis.
PloS one, Volume: 17, Issue: 7		2022
Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine-artesunate in a rural health district in Burkina Faso.
Pharmacology research & perspectives, Volume: 10, Issue: 4		2022
Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial.
BMC infectious diseases, Feb-21, Volume: 22, Issue: 1		2022
Efficacy and safety of dual intravenous artesunate plus quinine compared to intravenous artesunate for cerebral malaria in a triple blinded parallel multisite randomized controlled trial in Nigerian children: DUAL PAQ TRIAL Protocol.
Trials, Oct-20, Volume: 22, Issue: 1		2021
Dimeric artesunate-choline conjugate micelles coated with hyaluronic acid as a stable, safe and potent alternative anti-malarial injection of artesunate.
International journal of pharmaceutics, Nov-20, Volume: 609		2021
Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States-April 2019 Through December 2020.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 12-06, Volume: 73, Issue: 11		2021
Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study.
PLoS medicine, Volume: 18, Issue: 6		2021
Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 01-29, Volume: 74, Issue: 2		2022
Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT.
International immunopharmacology, Volume: 97		2021
Intravenous Artesunate for the Treatment of Severe Imported Malaria: Implementation, Efficacy, and Safety in 1391 Patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 11-16, Volume: 73, Issue: 10		2021
Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso.
Malaria journal, Jan-29, Volume: 20, Issue: 1		2021
The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma.
Investigational new drugs, Volume: 39, Issue: 1		2021
Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
PLoS medicine, Volume: 17, Issue: 8		2020
Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial.
PloS one, Volume: 14, Issue: 10		2019
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
PloS one, Volume: 14, Issue: 9		2019
Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 05-06, Volume: 70, Issue: 10		2020
Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA).
Drug safety, Volume: 41, Issue: 9		2018
Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate.
Birth defects research, 04-17, Volume: 110, Issue: 7		2018
Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.
Malaria journal, 07-03, Volume: 16, Issue: 1		2017
Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.
Malaria journal, 05-16, Volume: 16, Issue: 1		2017
Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications.
Journal of travel medicine, Mar-01, Volume: 24, Issue: 2		2017
Artesunate Enhances the Cytotoxicity of 5-Aminolevulinic Acid-Based Sonodynamic Therapy against Mouse Mammary Tumor Cells In Vitro.
Molecules (Basel, Switzerland), Mar-27, Volume: 22, Issue: 4		2017
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
PloS one, Volume: 12, Issue: 2		2017
Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.
Archives of toxicology, Volume: 91, Issue: 4		2017
Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
Cancer chemotherapy and pharmacology, Volume: 77, Issue: 2		2016
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
The Lancet. Infectious diseases, Volume: 16, Issue: 2		2016
Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial.
Reproductive health, Jan-15, Volume: 12		2015
Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso.
The Journal of infectious diseases, Mar-01, Volume: 211, Issue: 5		2015
Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India.
Journal of vector borne diseases, Volume: 50, Issue: 4		2013
Nanocapsules based on mPEGylated artesunate prodrug and its cytotoxicity.
Colloids and surfaces. B, Biointerfaces, Mar-01, Volume: 115		2014
Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.
Asian Pacific journal of cancer prevention : APJCP, Volume: 14, Issue: 9		2013
Erythrophagocytosis enhances heme-dependent cytotoxicity of antimalarial drugs in canine histiocytic sarcoma cell line DH82.
The Journal of veterinary medical science, Mar-01, Volume: 76, Issue: 2		2014
Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis.
Malaria journal, Jul-15, Volume: 12		2013
Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71.
Oncology reports, Volume: 30, Issue: 3		2013
Safety and efficacy field study of artesunate for dogs with non-resectable tumours.
Anticancer research, Volume: 33, Issue: 5		2013
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria.
Tropical medicine & international health : TM & IH, Volume: 18, Issue: 5		2013
Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.
Malaria journal, Feb-21, Volume: 12		2013
Study on the developmental toxicity of combined artesunate and mefloquine antimalarial drugs on rats.
Reproductive toxicology (Elmsford, N.Y.), Volume: 34, Issue: 4		2012
Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India.
Malaria journal, Jul-20, Volume: 11		2012
Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 4		2012
Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.
The American journal of tropical medicine and hygiene, Volume: 86, Issue: 1		2012
In vitro evaluation of the genotoxic and cytotoxic effects of artesunate, an antimalarial drug, in human lymphocytes.
Environmental and molecular mutagenesis, Volume: 52, Issue: 7		2011
Genotoxicity assessment of the antimalarial compound artesunate in somatic cells of mice.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, Volume: 49, Issue: 6		2011
Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 92, Issue: 1		2011
A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.
The American journal of tropical medicine and hygiene, Volume: 83, Issue: 6		2010
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial.
The Lancet. Infectious diseases, Volume: 11, Issue: 2		2011
Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety.
Malaria journal, Oct-21, Volume: 9		2010
Localization of artesunate and its derivatives in the pregnant rat and fetus following oral administration and relationship to developmental toxicity.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 89, Issue: 5		2010
New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 9		2010
Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines.
Molecules (Basel, Switzerland), Apr-22, Volume: 15, Issue: 4		2010
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
Lancet (London, England), Apr-24, Volume: 375, Issue: 9724		2010
Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon.
Wiener klinische Wochenschrift, Volume: 122, Issue: 5-6		2010
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, May-01, Volume: 50, Issue: 9		2010
Toxicity of the antimalarial artemisinin and its dervatives.
Critical reviews in toxicology, Volume: 40, Issue: 5		2010
Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers.
International journal of clinical pharmacology and therapeutics, Volume: 47, Issue: 9		2009
Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial.
Malaria journal, Apr-14, Volume: 8		2009
Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria.
Malaria journal, Sep-09, Volume: 7		2008
Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Artesunate: developmental toxicity and toxicokinetics in monkeys.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Embryotoxicity of artesunate in animal species related to drug tissue distribution and toxicokinetic profiles.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Sensitive periods for developmental toxicity of orally administered artesunate in the rat.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Malaria journal, Jun-11, Volume: 7		2008
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
The American journal of tropical medicine and hygiene, Volume: 78, Issue: 3		2008
A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria.
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume: 102, Issue: 5		2008
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
PloS one, Feb-20, Volume: 3, Issue: 2		2008
Randomized, comparative study of the efficacy and safety of artesunate plus amodiaquine, administered as a single daily intake versus two daily intakes in the treatment of uncomplicated falciparum malaria.
Malaria journal, Jan-19, Volume: 7		2008
Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal.
Malaria journal, Nov-15, Volume: 6		2007
Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya.
East African medical journal, Volume: 83, Issue: 5		2006
Toxicity evaluation of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats.
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume: 101, Issue: 2		2007
Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
The American journal of tropical medicine and hygiene, Volume: 73, Issue: 2		2005
Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 71, Issue: 6		2004
Randomised efficacy and safety study of two 3-day artesunate rectal capsule/mefloquine regimens versus artesunate alone for uncomplicated malaria in Ecuadorian children.
Acta tropica, Volume: 89, Issue: 1		2003
Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan.
The American journal of tropical medicine and hygiene, Volume: 68, Issue: 2		2003
Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea.
The Pediatric infectious disease journal, Volume: 22, Issue: 3		2003
A safety and efficacy trial of artesunate, sulphadoxine-pyrimethamine and primaquine in P falciparum malaria.
The Ceylon medical journal, Volume: 47, Issue: 3		2002
Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats.
Pharmacology, biochemistry, and behavior, Volume: 67, Issue: 1		2000
Studies of the neurotoxicity of oral artemisinin derivatives in mice.
The American journal of tropical medicine and hygiene, Volume: 62, Issue: 3		2000
Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.
The American journal of tropical medicine and hygiene, Volume: 60, Issue: 4		1999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (4)

ArticleYear
Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar.
Emerging infectious diseases, Volume: 26, Issue: 8		2020
Effects of Artesunate on some biochemical parameters in pregnant albino Wistar rats challenged with lethal strain Plasmodium berghei NK65: Appreciating the activities of artemisinin drugs on key pregnancy hormone balance.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, Jul-05, Volume: 69, Issue: 6		2017
Validation of ELISA for quantitation of artemisinin-based antimalarial drugs.
The American journal of tropical medicine and hygiene, Volume: 89, Issue: 6		2013
Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal.
Malaria journal, Nov-15, Volume: 6		2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (112)

ArticleYear
Comparative effect of artemether-lumefantrine and artesunate-amodiaquine on gametocyte clearance in children with uncomplicated Plasmodium falciparum malaria in Madagascar.
Malaria journal, Nov-14, Volume: 21, Issue: 1		2022
Plasmodium falciparum clearance time in Malawian children with cerebral malaria: a retrospective cohort study.
Malaria journal, Oct-18, Volume: 20, Issue: 1		2021
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
The Journal of antimicrobial chemotherapy, 04-13, Volume: 76, Issue: 5		2021
Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling.
Antimicrobial agents and chemotherapy, 02-17, Volume: 65, Issue: 3		2021
Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
PLoS medicine, Volume: 17, Issue: 8		2020
Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, Volume: 95		2020
Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, Volume: 89		2019
Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives.
The Journal of infectious diseases, 08-30, Volume: 220, Issue: 7		2019
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Malaria journal, Apr-18, Volume: 18, Issue: 1		2019
Plasmodium falciparum Clearance Is Pitting-Dependent With Artemisinin-Based Drugs but Pitting-Independent With Atovaquone-Proguanil or Mefloquine.
The Journal of infectious diseases, 07-02, Volume: 220, Issue: 3		2019
[Research progress on pharmacokinetics and pharmacological activities of artesunate].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, Volume: 43, Issue: 19		2018
Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial.
Malaria journal, Oct-30, Volume: 17, Issue: 1		2018
Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border.
Malaria journal, Sep-03, Volume: 17, Issue: 1		2018
Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice.
International journal for parasitology, Volume: 48, Issue: 12		2018
Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs.
The Journal of antimicrobial chemotherapy, 11-01, Volume: 73, Issue: 11		2018
The characterization, pharmacokinetic, and tissue distribution studies of TPGS-modified artesunate liposome in rats.
Drug development and industrial pharmacy, Volume: 44, Issue: 9		2018
Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.
Malaria journal, Mar-23, Volume: 17, Issue: 1		2018
Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo.
International journal for parasitology, Volume: 47, Issue: 14		2017
Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum.
Veterinary parasitology, Jan-15, Volume: 233		2017
Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model.
Malaria journal, 09-06, Volume: 15		2016
In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali.
The American journal of tropical medicine and hygiene, Volume: 94, Issue: 3		2016
Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Antimicrobial agents and chemotherapy, Dec-14, Volume: 60, Issue: 3		2015
Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.
Malaria journal, Oct-09, Volume: 14		2015
How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 10		2015
Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Nov-01, Volume: 61, Issue: 9		2015
Determination and pharmacokinetic studies of artesunate and its metabolite in sheep plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Aug-01, Volume: 997		2015
Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 9		2015
Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.
British journal of clinical pharmacology, Volume: 80, Issue: 4		2015
Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 1		2015
Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
The Journal of antimicrobial chemotherapy, Volume: 70, Issue: 3		2015
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.
European journal of clinical pharmacology, Volume: 70, Issue: 12		2014
Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malaria.
The Journal of infectious diseases, Jan-15, Volume: 211, Issue: 2		2015
Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 10		2014
Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.
Malaria journal, Jul-22, Volume: 13		2014
Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.
The Journal of antimicrobial chemotherapy, Volume: 69, Issue: 9		2014
Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.
Malaria journal, May-23, Volume: 13		2014
Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers.
The American journal of tropical medicine and hygiene, Volume: 90, Issue: 6		2014
Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India.
Journal of vector borne diseases, Volume: 50, Issue: 4		2013
Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.
Antimicrobial agents and chemotherapy, Volume: 57, Issue: 12		2013
Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin.
Computer methods and programs in biomedicine, Volume: 112, Issue: 1		2013
Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria.
Malaria journal, Mar-27, Volume: 12		2013
Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen.
Clinical pharmacology and therapeutics, Volume: 93, Issue: 5		2013
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity.
The Journal of infectious diseases, Jun-01, Volume: 207, Issue: 11		2013
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 56, Issue: 5		2013
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.
Malaria journal, Aug-30, Volume: 11		2012
Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 11		2012
Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study.
Malaria journal, Aug-01, Volume: 11		2012
No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali.
The American journal of tropical medicine and hygiene, Volume: 87, Issue: 1		2012
Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults.
Malaria journal, Apr-27, Volume: 11		2012
Evaluation of the pharmacokinetic profile of artesunate, artemether and their metabolites in sheep naturally infected with Fasciola hepatica.
Veterinary parasitology, May-25, Volume: 186, Issue: 3-4		2012
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator.
Malaria journal, Nov-10, Volume: 10		2011
Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.
British journal of clinical pharmacology, Volume: 73, Issue: 3		2012
Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.
Malaria journal, Sep-21, Volume: 10		2011
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration.
Malaria journal, Sep-13, Volume: 10		2011
Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 55, Issue: 9		2011
Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria.
Malaria journal, Jul-01, Volume: 10		2011
Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria.
Malaria journal, May-08, Volume: 10		2011
Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC.
Malaria journal, Feb-28, Volume: 10		2011
The multiple-dosing pharmacokinetics of artemether, artesunate, and their metabolite dihydroartemisinin in rats.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 41, Issue: 3		2011
New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 9		2010
Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate.
PloS one, Apr-15, Volume: 5, Issue: 4		2010
Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Malaria journal, Dec-18, Volume: 8		2009
Effects of mefloquine and artesunate mefloquine on the emergence, clearance and sex ratio of Plasmodium falciparum gametocytes in malarious children.
Malaria journal, Dec-16, Volume: 8		2009
Severe embryolethality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 86, Issue: 5		2009
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 1		2010
Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study.
The American journal of tropical medicine and hygiene, Volume: 81, Issue: 4		2009
Population pharmacokinetics of artesunate and amodiaquine in African children.
Malaria journal, Aug-20, Volume: 8		2009
Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.
European journal of clinical pharmacology, Volume: 65, Issue: 10		2009
Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.
European journal of clinical pharmacology, Volume: 65, Issue: 8		2009
Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.
Malaria journal, Apr-09, Volume: 8		2009
Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica.
The Journal of antimicrobial chemotherapy, Volume: 63, Issue: 3		2009
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
Antimicrobial agents and chemotherapy, Volume: 52, Issue: 12		2008
Pharmacokinetic and pharmacodynamic evaluation of intramuscular artesunate in healthy beagle dogs.
The American journal of tropical medicine and hygiene, Volume: 79, Issue: 1		2008
Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration.
European journal of clinical pharmacology, Volume: 64, Issue: 10		2008
Pharmacokinetics of artesunate in the domestic pig.
The Journal of antimicrobial chemotherapy, Volume: 62, Issue: 3		2008
Gametocyte clearance in uncomplicated and severe Plasmodium falciparum malaria after artesunate-mefloquine treatment in Thailand.
The Korean journal of parasitology, Volume: 46, Issue: 2		2008
Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.
European journal of clinical pharmacology, Volume: 64, Issue: 7		2008
Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon.
The Journal of antimicrobial chemotherapy, Volume: 60, Issue: 5		2007
Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria.
Annals of tropical paediatrics, Volume: 27, Issue: 1		2007
Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers.
Antimicrobial agents and chemotherapy, Volume: 51, Issue: 3		2007
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients.
PLoS medicine, Volume: 3, Issue: 11		2006
The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.
European journal of clinical pharmacology, Volume: 62, Issue: 12		2006
Cerebral malaria in spite of peripheral parasite clearance in a patient treated with atovaquone/proguanil.
Parasitology research, Volume: 100, Issue: 4		2007
Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 7		2006
Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.
European journal of clinical pharmacology, Volume: 62, Issue: 5		2006
Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine.
The Southeast Asian journal of tropical medicine and public health, Volume: 36, Issue: 1		2005
Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 49, Issue: 4		2005
The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers.
The Southeast Asian journal of tropical medicine and public health, Volume: 35, Issue: 3		2004
Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 11		2004
Pharmacokinetics of artesunate following oral and rectal administration in healthy Sudanese volunteers.
Tropical doctor, Volume: 34, Issue: 3		2004
The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.
European journal of clinical pharmacology, Volume: 59, Issue: 7		2003
Central role of the spleen in malaria parasite clearance.
The Journal of infectious diseases, May-15, Volume: 185, Issue: 10		2002
The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria.
British journal of clinical pharmacology, Volume: 53, Issue: 1		2002
Pharmacokinetics of artesunate after single oral administration to rats.
BMC pharmacology, Volume: 1		2001
Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.
The American journal of tropical medicine and hygiene, Volume: 65, Issue: 6		2001
Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
British journal of clinical pharmacology, Volume: 52, Issue: 6		2001
Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 45, Issue: 1		2001
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria.
The Journal of infectious diseases, Volume: 182, Issue: 2		2000
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Clinical pharmacology and therapeutics, Volume: 66, Issue: 5		1999
Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 43, Issue: 2		1999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (56)

ArticleYear
Artesunate carriers induced ferroptosis to overcome biological barriers for anti-cancer.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 190		2023
Role of artesunate in autoimmune diseases and signaling pathways.
Immunotherapy, Volume: 15, Issue: 14		2023
Missing-Linker-Assisted Artesunate Delivery by Metal-Organic Frameworks for Synergistic Cancer Treatment.
Angewandte Chemie (International ed. in English), 12-06, Volume: 60, Issue: 50		2021
Artesunate Restrains Maturation of Dendritic Cells and Ameliorates Heart Transplantation-Induced Acute Rejection in Mice through the PERK/ATF4/CHOP Signaling Pathway.
Mediators of inflammation, Volume: 2021		2021
Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria.
International journal for parasitology. Drugs and drug resistance, Volume: 16		2021
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
The Journal of antimicrobial chemotherapy, 04-13, Volume: 76, Issue: 5		2021
Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents.
Metallomics : integrated biometal science, 07-22, Volume: 12, Issue: 7		2020
[Preparation of liposomal artesunate dry powder inhalers and the effect on the acute lung injury of rats].
Yao xue xue bao = Acta pharmaceutica Sinica, Volume: 51, Issue: 12		2016
Liposomes of dimeric artesunate phospholipid: A combination of dimerization and self-assembly to combat malaria.
Biomaterials, Volume: 163		2018
Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
Leukemia research, Volume: 59		2017
Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Antimicrobial agents and chemotherapy, Dec-14, Volume: 60, Issue: 3		2015
The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-κB) pathway by targeting RelA/p65.
Antiviral research, Volume: 124		2015
Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.
British journal of clinical pharmacology, Volume: 80, Issue: 4		2015
Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
The Journal of antimicrobial chemotherapy, Volume: 70, Issue: 3		2015
Evaluation of dika wax-soybean oil-based artesunate-loaded lipospheres: in vitro-in vivo correlation studies.
Journal of microencapsulation, Volume: 31, Issue: 8		2014
Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.
Malaria journal, May-23, Volume: 13		2014
Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.
Drug delivery, Volume: 22, Issue: 5		2015
Artesunate-loaded chitosan/lecithin nanoparticles: preparation, characterization, and in vivo studies.
Drug development and industrial pharmacy, Volume: 38, Issue: 12		2012
Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.
British journal of clinical pharmacology, Volume: 73, Issue: 3		2012
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration.
Malaria journal, Sep-13, Volume: 10		2011
Modulating effects of plasma containing anti-malarial antibodies on in vitro anti-malarial drug susceptibility in Plasmodium falciparum.
Malaria journal, Nov-16, Volume: 9		2010
Firstborn microcrystallization method to prepare nanocapsules containing artesunate.
International journal of nanomedicine, Aug-09, Volume: 5		2010
Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers.
European journal of clinical pharmacology, Volume: 67, Issue: 3		2011
Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products.
Journal of controlled release : official journal of the Controlled Release Society, Aug-17, Volume: 146, Issue: 1		2010
Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Malaria journal, Dec-18, Volume: 8		2009
Severe embryolethality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 86, Issue: 5		2009
Bioavailability of a co-formulated combination of amodiaquine and artesunate under fed and fasted conditions. A randomised, open-label crossover study.
Arzneimittel-Forschung, Volume: 59, Issue: 7		2009
Population pharmacokinetics of artesunate and amodiaquine in African children.
Malaria journal, Aug-20, Volume: 8		2009
Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.
European journal of clinical pharmacology, Volume: 65, Issue: 8		2009
Validation of high performance liquid chromatography-electrochemical detection methods with simultaneous extraction procedure for the determination of artesunate, dihydroartemisinin, amodiaquine and desethylamodiaquine in human plasma for application in c
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Feb-15, Volume: 877, Issue: 5-6		2009
Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon.
The Journal of infectious diseases, Sep-15, Volume: 198, Issue: 6		2008
Pharmacokinetics of artesunate in the domestic pig.
The Journal of antimicrobial chemotherapy, Volume: 62, Issue: 3		2008
In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria.
Journal of vector borne diseases, Volume: 45, Issue: 1		2008
In vitro release and stability of an artesunate rectal gel suitable for pediatric use.
International journal of pharmaceutics, Apr-02, Volume: 353, Issue: 1-2		2008
Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug.
ChemMedChem, Volume: 2, Issue: 10		2007
Rectal administration of artemisinin derivatives for the treatment of malaria.
JAMA, Jun-06, Volume: 297, Issue: 21		2007
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients.
PLoS medicine, Volume: 3, Issue: 11		2006
Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 50, Issue: 7		2006
Fatty food does not alter blood mefloquine concentrations in the treatment of falciparum malaria.
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume: 99, Issue: 12		2005
Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine.
The Southeast Asian journal of tropical medicine and public health, Volume: 36, Issue: 1		2005
Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.
Antimicrobial agents and chemotherapy, Volume: 48, Issue: 8		2004
Pharmacokinetics of artesunate following oral and rectal administration in healthy Sudanese volunteers.
Tropical doctor, Volume: 34, Issue: 3		2004
Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria.
Antimicrobial agents and chemotherapy, Volume: 46, Issue: 12		2002
Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers.
The American journal of tropical medicine and hygiene, Volume: 66, Issue: 2		2002
Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 46, Issue: 4		2002
The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria.
British journal of clinical pharmacology, Volume: 53, Issue: 1		2002
Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.
The American journal of tropical medicine and hygiene, Volume: 65, Issue: 6		2001
Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
British journal of clinical pharmacology, Volume: 52, Issue: 6		2001
A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.
British journal of clinical pharmacology, Volume: 52, Issue: 6		2001
Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria.
Antimicrobial agents and chemotherapy, Volume: 45, Issue: 2		2001
Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 44, Issue: 4		2000
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.
Clinical pharmacology and therapeutics, Volume: 66, Issue: 5		1999
Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 43, Issue: 2		1999
A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria.
The American journal of tropical medicine and hygiene, Volume: 59, Issue: 5		1998
A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria.
British journal of clinical pharmacology, Volume: 45, Issue: 2		1998
Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells.
Journal of pharmaceutical sciences, Volume: 85, Issue: 6		1996
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (153)

ArticleYear
Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
Hematology (Amsterdam, Netherlands), Volume: 28, Issue: 1		2023
Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria.
Clinical pharmacology and therapeutics, Volume: 114, Issue: 6		2023
An artesunate pharmacometric model to explain therapeutic responses in falciparum malaria.
The Journal of antimicrobial chemotherapy, 09-05, Volume: 78, Issue: 9		2023
The five continuum of care criteria that should accompany rectal artesunate interventions: lessons learned from an implementation study in Malawi.
Malaria journal, Mar-25, Volume: 22, Issue: 1		2023
Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria.
PloS one, Volume: 18, Issue: 2		2023
Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate in the Democratic Republic of the Congo, Nigeria, and Uganda: An operational study.
PLoS medicine, Volume: 20, Issue: 2		2023
[Therapeutic Effect of Artesunate on Influenza A Viral Pneumonia].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, Volume: 53, Issue: 6		2022
Development of artesunate intelligent prodrug liposomes based on mitochondrial targeting strategy.
Journal of nanobiotechnology, Aug-13, Volume: 20, Issue: 1		2022
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma.
Biomaterials, Volume: 287		2022
Assessment of quantitative and semi-quantitative biological test methods of artesunate in vitro.
Parasite (Paris, France), Volume: 29		2022
Cross-sectional study to predict subnational levels of health workers' knowledge about severe malaria treatment in Kenya.
BMJ open, 01-05, Volume: 12, Issue: 1		2022
Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study.
PLoS medicine, Volume: 18, Issue: 6		2021
Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 01-29, Volume: 74, Issue: 2		2022
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Clinical pharmacology and therapeutics, Volume: 110, Issue: 4		2021
Development and Validation of an
Antimicrobial agents and chemotherapy, 05-18, Volume: 65, Issue: 6		2021
Artesunate Provides Neuroprotection against Cerebral Ischemia-Reperfusion Injury via the TLR-4/NF-κB Pathway in Rats.
Biological & pharmaceutical bulletin, Mar-01, Volume: 44, Issue: 3		2021
Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling.
Antimicrobial agents and chemotherapy, 02-17, Volume: 65, Issue: 3		2021
Predictors of health workers' knowledge about artesunate-based severe malaria treatment recommendations in government and faith-based hospitals in Kenya.
Malaria journal, Jul-23, Volume: 19, Issue: 1		2020
A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3).
Gynecologic oncology, Volume: 157, Issue: 1		2020
Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
BMC infectious diseases, Dec-03, Volume: 19, Issue: 1		2019
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
Biochemical and biophysical research communications, 10-29, Volume: 519, Issue: 1		2019
The effect of dose on the antimalarial efficacy of artesunate-mefloquine against
BMJ open, 06-27, Volume: 9, Issue: 6		2019
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Malaria journal, Apr-18, Volume: 18, Issue: 1		2019
Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali.
Malaria journal, Feb-18, Volume: 18, Issue: 1		2019
Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine.
International journal for parasitology. Drugs and drug resistance, Volume: 9		2019
Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.
Current rheumatology reports, 07-28, Volume: 20, Issue: 9		2018
Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.
Malaria journal, May-15, Volume: 17, Issue: 1		2018
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
Lancet (London, England), 04-07, Volume: 391, Issue: 10128		2018
[Tissue distribution of TPGS modified artesunate liposome and its metabolites in rats].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, Volume: 43, Issue: 2		2018
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.
Cancer chemotherapy and pharmacology, Volume: 81, Issue: 3		2018
Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate.
Birth defects research, 04-17, Volume: 110, Issue: 7		2018
Artesunate-quercetin/luteolin dual drug nanofacilitated synergistic treatment for malaria: A plausible approach to overcome artemisinin combination therapy resistance.
Medical hypotheses, Volume: 109		2017
Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.
Malaria journal, 07-03, Volume: 16, Issue: 1		2017
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
PloS one, Volume: 12, Issue: 2		2017
Artesunate restores spatial learning of rats with hepatic encephalopathy by inhibiting ammonia-induced oxidative damage in neurons and dysfunction of glutamate signaling in astroglial cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Volume: 84		2016
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.
The Lancet. Infectious diseases, Volume: 16, Issue: 10		2016
Disruption of spermatogenesis in the liver fluke, Fasciola hepatica by two artemisinin derivatives, artemether and artesunate.
Journal of helminthology, Volume: 91, Issue: 1		2017
Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia.
Antimicrobial agents and chemotherapy, Volume: 60, Issue: 7		2016
Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Antimicrobial agents and chemotherapy, Dec-14, Volume: 60, Issue: 3		2015
How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?
Antimicrobial agents and chemotherapy, Volume: 59, Issue: 10		2015
Compound antimalarial ethosomal cataplasm: preparation, evaluation, and mechanism of penetration enhancement.
International journal of nanomedicine, Volume: 10		2015
A comparative study on the impact of two artemisinin derivatives, artemether and artesunate, on the female reproductive system of Fasciola hepatica.
Veterinary parasitology, Jul-30, Volume: 211, Issue: 3-4		2015
Ultrastructural changes in the tegument and gut of adult Fasciola hepatica following in vivo treatment with artesunate.
Experimental parasitology, Volume: 154		2015
Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria.
The Journal of antimicrobial chemotherapy, Volume: 70, Issue: 3		2015
Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 10		2014
Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol.
Antimicrobial agents and chemotherapy, Volume: 58, Issue: 10		2014
Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India.
Malaria journal, Jul-22, Volume: 13		2014
Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial.
PLoS neglected tropical diseases, Volume: 8, Issue: 7		2014
A review of dihydroartemisinin as another gift from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.
Parasitology research, Volume: 113, Issue: 5		2014
Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.
Drug delivery, Volume: 22, Issue: 5		2015
Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia.
Malaria journal, Sep-23, Volume: 12		2013
Safety and efficacy field study of artesunate for dogs with non-resectable tumours.
Anticancer research, Volume: 33, Issue: 5		2013
Graphene-polyaniline nanocomposite based biosensor for detection of antimalarial drug artesunate in pharmaceutical formulation and biological fluids.
Talanta, Jul-15, Volume: 111		2013
Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen.
Clinical pharmacology and therapeutics, Volume: 93, Issue: 5		2013
Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial.
Malaria journal, Oct-31, Volume: 11		2012
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.
Malaria journal, Aug-30, Volume: 11		2012
Adjunctive management of malaria.
Current opinion in infectious diseases, Volume: 25, Issue: 5		2012
Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation.
The Journal of antimicrobial chemotherapy, Volume: 67, Issue: 11		2012
Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway.
Translational research : the journal of laboratory and clinical medicine, Volume: 161, Issue: 2		2013
Fasciola gigantica: the in vitro effects of artesunate as compared to triclabendazole on the 3-weeks-old juvenile.
Experimental parasitology, Volume: 131, Issue: 1		2012
Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.
British journal of clinical pharmacology, Volume: 73, Issue: 3		2012
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration.
Malaria journal, Sep-13, Volume: 10		2011
The pharmacogenetics of antimalaria artemisinin combination therapy.
Expert opinion on drug metabolism & toxicology, Volume: 7, Issue: 10		2011
Voltammetric behaviour of antimalarial drug artesunate in solubilized systems.
Colloids and surfaces. B, Biointerfaces, Dec-01, Volume: 88, Issue: 2		2011
Distribution of mefloquine in the blood of Thai patients with acute uncomplicated falciparum malaria following administration of therapeutic doses of artesunate.
European journal of clinical pharmacology, Volume: 67, Issue: 7		2011
Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination.
Malaria journal, Mar-29, Volume: 10		2011
Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC.
Malaria journal, Feb-28, Volume: 10		2011
Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 92, Issue: 1		2011
The multiple-dosing pharmacokinetics of artemether, artesunate, and their metabolite dihydroartemisinin in rats.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 41, Issue: 3		2011
Intrahost modeling of artemisinin resistance in Plasmodium falciparum.
Proceedings of the National Academy of Sciences of the United States of America, Jan-04, Volume: 108, Issue: 1		2011
Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Dec-15, Volume: 51, Issue: 12		2010
In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 11		2010
Localization of artesunate and its derivatives in the pregnant rat and fetus following oral administration and relationship to developmental toxicity.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 89, Issue: 5		2010
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia.
PloS one, Jul-30, Volume: 5, Issue: 7		2010
The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China.
Parasitology research, Volume: 107, Issue: 4		2010
New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 9		2010
Effect of artemether, artesunate, OZ78, praziquantel, and tribendimidine alone or in combination chemotherapy on the tegument of Clonorchis sinensis.
Parasitology international, Volume: 59, Issue: 3		2010
Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Malaria journal, Dec-18, Volume: 8		2009
Severe embryolethality of artesunate related to pharmacokinetics following intravenous and intramuscular doses in pregnant rats.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 86, Issue: 5		2009
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 1		2010
Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers.
International journal of clinical pharmacology and therapeutics, Volume: 47, Issue: 9		2009
Combination chemotherapy against Clonorchis sinensis: experiments with artemether, artesunate, OZ78, praziquantel, and tribendimidine in a rat model.
Antimicrobial agents and chemotherapy, Volume: 53, Issue: 9		2009
Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.
European journal of clinical pharmacology, Volume: 65, Issue: 10		2009
Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model.
Experimental parasitology, Volume: 121, Issue: 4		2009
Evidence for the spectroscopic determination of artesunate in dosage form.
Journal of vector borne diseases, Volume: 45, Issue: 4		2008
Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica.
The Journal of antimicrobial chemotherapy, Volume: 63, Issue: 3		2009
[Effect of tribendimidine, artesunate, artemether and praziquantel, administered intragastrically at single, multiple or combined doses, to rats infected with Clonorchis sinensis].
Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, Oct-30, Volume: 26, Issue: 5		2008
[Artesunate in interrupting the transmission of Plasmodium falciparum].
Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, Oct-30, Volume: 26, Issue: 5		2008
Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal.
Tropical medicine & international health : TM & IH, Volume: 14, Issue: 1		2009
Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria.
Malaria journal, Sep-09, Volume: 7		2008
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
Antimicrobial agents and chemotherapy, Volume: 52, Issue: 12		2008
Artesunate: developmental toxicity and toxicokinetics in monkeys.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Embryotoxicity of artesunate in animal species related to drug tissue distribution and toxicokinetic profiles.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Sensitive periods for developmental toxicity of orally administered artesunate in the rat.
Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 4		2008
Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration.
European journal of clinical pharmacology, Volume: 64, Issue: 10		2008
Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand.
The Southeast Asian journal of tropical medicine and public health, Volume: 39, Issue: 1		2008
Pharmacokinetics of artesunate in the domestic pig.
The Journal of antimicrobial chemotherapy, Volume: 62, Issue: 3		2008
Randomized, comparative study of the efficacy and safety of artesunate plus amodiaquine, administered as a single daily intake versus two daily intakes in the treatment of uncomplicated falciparum malaria.
Malaria journal, Jan-19, Volume: 7		2008
Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal.
Malaria journal, Nov-15, Volume: 6		2007
Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon.
The Journal of antimicrobial chemotherapy, Volume: 60, Issue: 5		2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (41)

ArticleYear
Efficacy of artesunate combined with Atractylodes lancea or Prabchompoothaweep remedy extracts as adjunctive therapy for the treatment of cerebral malaria.
BMC complementary medicine and therapies, Sep-20, Volume: 23, Issue: 1		2023
Lower dose of metformin combined with artesunate induced autophagy-dependent apoptosis of glioblastoma by activating ROS-AMPK-mTOR axis.
Experimental cell research, 09-01, Volume: 430, Issue: 1		2023
Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria.
PloS one, Volume: 18, Issue: 2		2023
Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study.
PLoS neglected tropical diseases, Volume: 16, Issue: 10		2022
Drug-Drug Interactions of Artemisinin-Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature.
Journal of clinical pharmacology, Volume: 62, Issue: 10		2022
[Effects of Artesunate Combined with Arsenious Acid on Proliferation and Apoptosis of Multiple Myeloma Cells via PI3K/AKT Signaling Pathway].
Zhongguo shi yan xue ye xue za zhi, Volume: 29, Issue: 6		2021
Effectiveness of artesunate combined with fractional CO2 laser in a hypertrophic scar model with underlying mechanism.
Burns : journal of the International Society for Burn Injuries, Volume: 48, Issue: 3		2022
Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial.
PloS one, Volume: 14, Issue: 10		2019
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.
Antimicrobial agents and chemotherapy, Volume: 63, Issue: 2		2019
Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs.
The Journal of antimicrobial chemotherapy, 11-01, Volume: 73, Issue: 11		2018
Efficacy of Lophira alata Leaf Extract and its Combination with Artesunate in Mice Prior Exposed to Plasmodium berghei.
Drug research, Volume: 68, Issue: 4		2018
Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone.
Antiviral research, Volume: 123		2015
Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers.
The American journal of tropical medicine and hygiene, Volume: 90, Issue: 6		2014
The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo.
Asian Pacific journal of cancer prevention : APJCP, Volume: 14, Issue: 8		2013
A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.
PloS one, Volume: 7, Issue: 8		2012
Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.
The American journal of tropical medicine and hygiene, Volume: 86, Issue: 3		2012
High dose artesunate in combination with mefloquine: pharmacovigilance in the Venezuelan Amazon.
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume: 106, Issue: 3		2012
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Malaria journal, Aug-24, Volume: 10		2011
Artesunate in combination with oxacillin protect sepsis model mice challenged with lethal live methicillin-resistant Staphylococcus aureus (MRSA) via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacilli
International immunopharmacology, Volume: 11, Issue: 8		2011
Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum.
Parasitology research, Volume: 108, Issue: 2		2011
In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 11		2010
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Antimicrobial agents and chemotherapy, Volume: 54, Issue: 5		2010
Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model.
Experimental parasitology, Volume: 121, Issue: 4		2009
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
PloS one, Feb-20, Volume: 3, Issue: 2		2008
[Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial].
Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, Volume: 6, Issue: 2		2008
An open, randomized trial of three-day treatment with artesunate combined with a standard dose of mefloquine divided over either two or three days, for acute, uncomplicated falciparum malaria.
The Southeast Asian journal of tropical medicine and public health, Volume: 36, Issue: 3		2005
Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
The American journal of tropical medicine and hygiene, Volume: 73, Issue: 2		2005
The chemotherapy of rodent malaria. LXIII. Drug combinations to impede the selection of drug resistance, part 6: the potential value of chlorproguanil and dapsone in combination, and with the addition of artesunate.
Annals of tropical medicine and parasitology, Volume: 99, Issue: 5		2005
The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate.
Annals of tropical medicine and parasitology, Volume: 98, Issue: 8		2004
Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria.
Tropical medicine & international health : TM & IH, Volume: 9, Issue: 10		2004
Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Dec-01, Volume: 37, Issue: 11		2003
Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria.
Tropical medicine & international health : TM & IH, Volume: 6, Issue: 2		2001
Acceptance of short course artesunate plus mefloquine drug combination by malaria patients in rural Myanmar.
The Southeast Asian journal of tropical medicine and public health, Volume: 30, Issue: 3		1999
Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.
Antimicrobial agents and chemotherapy, Volume: 43, Issue: 2		1999
A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand.
The Southeast Asian journal of tropical medicine and public health, Volume: 28, Issue: 3		1997
Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria.
The American journal of tropical medicine and hygiene, Volume: 58, Issue: 1		1998
Pharmacokinetics of mefloquine alone or in combination with artesunate.
Bulletin of the World Health Organization, Volume: 72, Issue: 1		1994
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Natural Sources (3)

ArticleYear
Drug-Drug Interactions of Artemisinin-Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature.
Journal of clinical pharmacology, Volume: 62, Issue: 10		2022
The antiviral activities of artemisinin and artesunate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Sep-15, Volume: 47, Issue: 6		2008
The chemotherapy of rodent malaria, XL. The action of artemisinin and related sesquiterpenes.
Annals of tropical medicine and parasitology, Volume: 80, Issue: 5		1986
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]